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SOMMARIO  
 
Questa tesi di dottorato è incentrata sullo studio di composti di natura terpenica 
isolati da piante del genere Salvia al fine di evidenziare le basi razionali che 
giustifichino l’utilizzo tradizionale delle piante medicinali.  
Alla parte più propriamente sperimentale è stata premessa una rassegna sui 
principali composti di natura terpenica e le rispettive attività biologiche possedute. 
In collaborazione con diversi gruppi di ricerca è stato possibile effettuare un 
lavoro di screening su otto piante, appartenenti al suddetto genere, che ha permesso di 
ottenere informazioni interessanti, dal punto di vista farmacologico, su i principali 
terpenoidi isolati da Salvia divinorum, Salvia jamensis e Salvia cinnabarina.  
Per quanto riguarda la Salvia divinorum, poiché in letteratura è riportato che le 
foglie fresche, masticate lentamente, costituiscono un rimedio della tradizione mazteca 
adoperato per il trattamento della diarrea, nel nostro studio abbiamo valutato l’effetto 
di un estratto etanolico ottenuto dalle foglie di Salvia divinorum (SDE) e del suo 
principio attivo la salvinorina A (noto diterpenoide clerodano), sulla trasmissione 
colinergica enterica nell’ileo isolato di cavia. I dati ottenuti mostrano che la Salvia 
divinorum esercita un effetto inibente sulle contrazioni della muscolatura liscia 
intestinale. Tale effetto è strettamente legato all’attività agonista della salvinorina A, 
sui recettori ! degli oppioidi, i quali svolgono un ruolo cruciale sul controllo del 
rilascio di mediatori chimici eccitatori quali l’acetilcolina a livello pregiunzionale. 
Particolare attenzione è stata rivolta poi alla Salvia cinnabarina e al principale 
costituente attivo da essa isolato il diterpenoide pimarano, acido 3,4-seico-isopimaric- 
4(18),7,15-triene-3-oico (CMP1). Il nostro lavoro è stato finalizzato ad investigare i 
potenziali effetti a livello del Sistema Nervoso Centrale (SNC) del diterpenoide 
(composto 1). Nei nostri esperimenti condotti in vivo su topi, il composto 1 mostra 
effetti ansiolitici valutati mediante diversi modelli sperimentali (elevated plus maze e 
Porsolt test; test di locomozione: open field) possiede inoltre proprietà sedative, in 
quanto incrementa il tempo di sonno indotto da pentobarbitale. Gli effetti sono stati 
confrontati con quelli del diazepam, utilizzato come controllo positivo. L’elemento 
interessante dal punto di vista farmacologico emerso dal nostro studio è rappresentato 
dal fatto che il composto 1, alla dose ansiolitica, non modifica l’attività motoria 
spontanea al contrario del diazepam che induce effetti sedativi e nello stesso tempo 
provoca una riduzione dell’attività motoria. Il diterpenoide in questione ha inoltre 
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dimostrato, in un ulteriore studio condotto su topi anestetizzati in monitoraggio 
continuo della pressione, un interessante effetto ipotensivo. Tale effetto, legato ad un 
meccanismo periferico del composto, ha dimostrato di essere indipendente sia da una 
sua azione  sul sistema nervoso autonomo via stimolazione centrale ,sia dal rilascio di 
ossido nitrico. 
La terza pianta medicinale presa in esame è la Salvia jamensis. Nonostante sia 
poco conosciuta dal mondo scientifico, essa contiene diversi composti di natura 
terpenica (di- e triterpenoidi), alcuni dei quali possiedono notevoli attività biologiche. 
Il nostro gruppo ha indagato l’effetto dell’essudato ottenuto da foglie (SDE) e dei 
principali terpenoidi isolati (composti 1-7), sull’aggregazione piastrinica di ratto in 
vitro. I dati ottenuti hanno messo in evidenza che l’essudato (SDE) possiede un lieve 
effetto inibente, concentrazione-dipendente, sull’aggregazione indotta da ADP (3µM). 
Tale effetto è dovuto alla presenza di due principi attivi dotati di attività contrapposte. 
In particolare abbiamo visto che l’acido isopimarico (composto 2), diterpenoide 
pimarano ben conosciuto, possiede un’azione anti-aggregante e concentrazione-
dipendente significativa, al contrario il nuovo diterpenoide clerodano (composto 1), 
trovato sinora solo nelle foglie di Salvia jamensis, induce un aumento 
dell’aggregazione piastrinica indotta da ADP (3µM). 
I risultati riportati in questa tesi sono stati in parte presentati a congressi 
nazionali e divulgati su riviste internazionali di interesse scientifico. 
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ABSTRACT 
 
Recently most interest has been focused on active compounds extracted from 
natural sources. This is due to the fact that many of these natural products in plants of 
medicinal value can offer new sources of drugs.  
The genus Salvia from the Lamiaceae family has numerous different species -    
about 900 species- which are extensively distributed in various regions of the world. 
Many Salvia species are well-studied and widely used in traditional medicine. Plants 
belonging to the genus Salvia are of particular interest, due to the wide variety of 
secondary metabolites produced in these plants, such as flavonoids, tannins and 
terpenoids.The terpenoid class, extracted from Salvia, includes a wide range of mono-, 
di-, tri-, sesqui- and tetraterpenoids. Many diterpenoids and triterpenoids, isolated 
from plants of several species of the genus Salvia, have been investigated for their 
pharmacological activities: analgesic; anti-inflammatory; hemostatic; antioxidant; 
antimicrobial and as an antitumoral remedy. It has been widely shown that many 
terpenoid compounds have significant anti-inflammatory effects. For this reason, they 
are potential molecules for the development of new drugs especially designed for the 
treatment and/or control of chronic inflammatory states such as rheumatism, asthma, 
inflammatory bowel diseases, atherosclerosis, etc. Some di- and triterpens from Salvia 
ssp are able to influence the central nervous system (CNS).  
In this thesis, the pharmacological effects of bioactive diterpenoids and 
triterpenoids from the Salvia species are investigate. In a screening programme on 
Salvia medicinal plants, like S. divinorum, S. cinnabarine and S. jamensis, we have 
find interesting biological effects. 
Following anecdotal reports that extracts of Salvia divinorum may possess 
antidiarrhoeal activity and because !-opioid receptors may modulate intestinal 
peristalsis we investigated the effect of Salvia divinorum, and its main active 
ingredient, salvinorin A, on myenteric cholinergic transmission. For this purpose we 
evaluated the effect of a standardized extract from Salvia divinorum leaves (SDE) and 
of isolated salvinorin A on the contractions elicited either by electrical stimulation or 
by exogenous acetylcholine in the guinea-pig ileum. These observations strongly 
support the hypothesis that SDE inhibits the twitch response by acting prejunctionally 
rather than through a direct action on intestinal smooth muscle. The hallucinogenic 
herb Salvia divinorum exerted inhibitory effects on enteric cholinergic transmission in 
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the guinea-pig ileum through activation of prejunctional !-opioid receptors. Salvinorin 
A may be the chemical constituent responsible for this activity. These results could 
provide the pharmacological basis underlying its traditional antidiarrhoeal use. 
During this PhD project the author has studied the effects in vivo of a new 
diterpenoid compound 3,4-secoisopimar-4(18),7,15-triene-3-oic acid (CMP 1) from 
Salvia cinnabarina. The possibility that CMP 1, like other isolated diterpenoids, may 
affect the CNS, was the main aim of these investigations. A putative anxiolytic and 
antidepressive activity of CMP 1 were studied in the elevated plus-maze test and in the 
forced swimming test. Furthermore, CMP 1 was administered after a pre-treatment 
with pentobarbital and its effects on sedative activity was monitored. The CMP 1 was 
also tested for its effects on spontaneous motor activity (total motility and locomotion) 
and several models of nociception have been used to examine the potential analgesic 
effects. These studies demonstrate for the first time that CMP 1 has pronounced CNS 
depressant properties, manifested as antinociception, sedation and axiolitic effects. In 
another study we evaluated the effect of CMP1 on arterial blood pressure in 
anaesthetized rats. On different groups of them treated with the ganglion-blocking 
agent chlorisondamine, the effect of CMP1 was evaluated before and following an 
infusion of the nitric oxide synthase inhibitor L-NAME. Intravenous administration of 
CMP1 led to a fall in mean arterial blood pressure that was not modified by treatment 
of the rat with chlorisondamine nor with L-NAME. The results demonstrate , for the 
first time, a hypotensive effect of CMP1 due to a peripheral mechanism but 
independent of endothelial nitric oxide release. 
The chemical constituents of Salvia x jamensis J. Compton and their platelet 
antiaggregating activity in vitro were also investigated. The surface exudate of Salvia 
x jamensis J. Compton, obtained by rinsing the plant material with methylene chloride 
and terpenic compounds 1-7 isolated have been tested on ADP-induced platelet 
aggregation. Among all the tested compounds, isopimaric acid 2 showed a significant 
concentration-dependent antiaggregating activity when ADP (3 "M) was used as 
agonist on rat platelets. Conversely, a new clerodane derivate 1 increased ADP–
induced platelet aggregation. 
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INTRODUCTION 
 
The Salvia genus belongs to the Lamiaceae or Labiatae family (about 200 
kinds break into more than 3,000 species) and it is composed of at least 900 species 
and dozens of cultivars consisting of hybrids [1-2]. This is a genus consisting of 
species with annual, biennial and perennial cycle shrub shape in origin countries. 
Although species belonging to genus Salvia are common throughout the world, they 
are more concentrated in Europe (in countries bordering the Mediterranean ), in South-
Eastern Asia, Central and South America and South Africa [2].  
The history of the use of several plants of the Salvia genus as a medicinal 
treatment spans several millennia, and both ancient and modern cultures. The name 
Salvia comes from the Latin salveo or salvus, the verb salvare, in reference to the 
curative properties of the specie that is certainly better known and used: Salvia 
officinalis. The Medical School of Salerno, one of the most famous in the Middle 
Ages, depositary throughout antiquity of medical knowledge, called this plant Salvia 
salvatrix, that is "Salvia saving"-salvia salvatrix naturae conciliatrix- and it was 
considered to be the miracle herb par excellence [2]. Before and after the Romans, 
from the Egyptians to medieval pharmacopoeia, Salvia officinalis was always 
appreciated in herbal medicine. It is no coincidence that in the 1700’s the Swedish 
biologist and naturalist Linneaeus (father of binomial nomenclature for the systemic 
classification of plants and animals)  assigned the name officinalis to this plant. Today, 
many of the numerous medicinal properties that have been attributed to it in the past 
have been confirmed by scientific studies. Therefore, several species of Salvia are 
found in the Pharmacopoeias of numerous countries around the world. In the 
therapeutic field several drugs isolated from plants of the genus Salvia are used to treat 
various disorders. This is due to its several pharmacological properties [3]. The Salvia 
genus has been found to be a rich source of terpenes, tannins and flavonoids [3]. 
Terpenes are mainly compounds of plant and animal origin [4]. All terpenes are 
hydrocarbons having carbon skeletons based on combinations of a C-5 unit, called 
isoprene unit (figure 1).  
Terpenoids are compounds related to terpenes, which may include some 
oxygen functionality or some rearrangement. However, the two terms are often used 
interchangeably. Just like terpenes, the terpenoids bind to each other by following the 
"head-tail" order and, depending on how many units work together to form the bonds, 
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are divided into: monoterpenoids (2 units); sesquiterpenoids (3 units); diterpenoids (4 
units), sesterterpenoids ( 5 units); triterpenoids (6 units) and tetraterpenoids or 
carotenoids (8units).  
Diterpenoids found in Salvia species 
Diterpenes or diterpenoids derive from condensation of four isoprene units, but 
the structural changes involved in the last stages of the biosynthetic pathway lead to a 
wide variety of complex chemical structures, including acyclic compounds, bi-, tri-and 
tetra-cyclic.  
a) Bi-cyclic diterpenoids. 
Bi-cyclic diterpenoids are classified in labdanes and clerodanes types (see 
Table A). A labdane diterpenoid, 8(17),12E,14-labdatrien-6,19-olide was obtained 
from the chloroform extract of Salvia leriaefolia and its antimicrobial activity against 
the Gram-positive bacterium Staphylococcus aureus has been reported [5].  
The Lamiaceae are a rich source of clerodane diterpenoids. A number of these 
metabolites have been isolated from Salvia species including salvinorin A, divinatorin 
and salvinicin A, from Salvia divinorum, [6]. Salvinorin A has been evaluated for its 
hallucinogenic [7], anti-inflammatory [8] antinociceptive and hypothermic [9] 
activities. Salvinorin A, a non-nitrogenous opioid receptor agonist, displays significant 
binding at the G#i-coupled ! opioid receptor (KOR) [10]. Anti-diarrhoeic effect is also 
reported: Salvinorina A is able to inhibit intestinal hypermotility in vitro [11] and in 
vivo [12]. Its inhibitory effect in the inflamed gut in vivo reveals a functional 
interaction between salvinorina A binding at KORs and cannabinoid CB(1) receptors 
[13]. In a recent study, oxadiazole and salvidivin A, a photooxygenation product of 
salvinorin A, have been identified as the first neoclerodane diterpenes with kappa 
antagonist activity [14]. A number of clerodane diterpenoids have been obtained from 
Salvia species including splenolide A [15] and salvixalapadiene and 
isosalvixalapadiene from Salvia xalapensis [16]. Salvisplendins A-D were isolated 
from Salvia splendens [17] and have been tested for affinity at human µ, $ and ! 
opioid receptors [18]. Salvileucalin B, a novel diterpenoid with a neoclerodane 
skeleton from Salvia leucantha, has shown cytotoxic activity in A549 e HT-29 cancer 
cells [19]. A new diterpenoid with clerodane skeleton from Salvia jamensis: 15, 16-
epoxy-cleroda-3-en-7!, 10"-dihydroxy-12,17,19,18-diolide was found to increase 
ADP–induced platelet aggregation in vitro [20].  
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Figure 1: clerodane-type diterpenoids from Salvia species. 
 
Table A: Bi-cyclic diterpenoids isolated from Salvia species and their biological activies  
 
Bi-cyclic 
diterpenoids 
Secondary metabolite constituents 
 
Salvia species Biological activities 
 
Labdane-
type 
 
• 8(17),12E,14-labdatrien-
6,19-olide 
 
Salvia leriaefolia • antimicrobial activity 
• salvinorin A,  
divinatorin e salvinicin A 
 
Salvia divinorum 
 
• hallucinogenic, anti-
inflammatory, antinociceptive, 
hypothermic and anti-
diarrheic proprieties  
 
• splenolide A e 
salvisplendins A-D  
 
Salvia splendens  
 
• affinity at human µ, $ and ! 
opioid receptors 
 
• salvixalapadiene e 
isosalvixalapadiene 
Salvia xalapensis  
 
 
• salvileucalin B 
 
Salvia leucantha 
 
• cytotoxic activity in A549 e 
HT-29 cancer cells 
 
 
 
Clerodane- 
type 
• 15,16-epossi-cleroda-3-en-
7!,10"diidrossi-
12,17,19,18-diolide 
Salvia jamensis 
 
• increase ADP–induced 
platelet aggregation in vitro 
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b) Tri-cyclic diterpenoids. 
The main terpenic constituents of the Salvia species are represented by tri-
cyclic diterpenoids, which can be classified in abietane and pimarane diterpenoids 
(table B).  
Among the abietane-type, phenolic, quinone and icetaxane diterpenoids have 
been reported.  
It is known that phenolic diterpene compounds, including carnosic acid, 
carnosol, ferruginol, 7-methoxyrosmanol and galdosol, obtained from the Salvia 
species, exhibit a variety of biological activities. It is demonstrated that carnosic acid 
and carnosol inhibited pancreatic lipase activity, which is participated in digestion of 
lipids [21]. Both compounds are activators of the human peroxisome proliferator-
activated receptor gamma (PPAR-gamma) and this activation increases the 
transcription of enzymes involved in primary metabolism, leading to lower  levels of 
fatty acids and glucose in the blood [22]. Carnosic acid and carnosol show pronounced 
antioxidant and anti-inflammatory effects. A recent study indicated that carnosic acid 
and carnosol inhibit the formation of pro-inflammatory leukotrienes in intact human 
polymorphonuclear leukocytes (PMNL) and both potently antagonise intracellular 
Ca2+ mobilisation induced by a chemotactic stimulus. Carnosic acid and carnosol 
attenuate formation of reactive oxygen species and the secretion of human leukocyte 
elastase [23]. Some of the phenolic-type diterpenoids show antimicrobial activity: 
carnosic acid 12-Me ester, isolated from the acetone extract of Salvia microphylla, 
possessed antimicrobial activity against Staphylococcus aureus [24]. Carnosic acid, 
from Salvia africana-lutea, exhibited MICs of 28 "M, against Mycobacterium 
tuberculosis [25], while carnosol greatly reduced the MICs of various aminoglycosides 
(potentiated the antimicrobial activity of aminoglycosides) and some other types of 
antimicrobial agents in vancomycin-resistant enterococci (VRE) [26]. A scientific 
report indicates that some diterpenoids with abietane-phenolic skeleton have activities 
on the central nervous system (CNS). 7-methoxyrosmanol competitively inhibited 3H-
flumazenil binding to the benzodiazepine receptor and galdosol showed the strongest 
binding activity to the benzodiazepine receptor [27].  
Examination of the Salvia species has afforded a series of abietane-quinone 
type diterpenoids, the secondary metabolites that are widely known and studied. 
Aethiopinone, salvipisone, 1-oxoaethiopinone and ferruginol, abietane-phenolic type, 
obtained from Salvia sclarea, proved to be bacteriostatic as well as bactericidal for the 
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cultures of Staphylococcus aureus and Staphylococcus epidermidis strain [28]. 
Walencka et al (2007) [29] reported that salvipisone and aethiopinone from Salvia 
sclarea showed synergy activity with %-lactam antibiotics through alteration of cell 
surface hydrophobicity and permeability, but not by changing penicillin-binding 
protein. Two abietane-quinone type diterpenoids, yunnannin A and danshenol C, were 
isolated from Salvia yunnanensis and were tested for their antitumor activity in T-24, 
QGY, K562, Me180 and BIU87 cell lines and showed inhibited growth [30]. 
Examination of the Algerian Salvia species has afforded 7-oxoroyleanone-12-Me ester 
and inuroyleanol, isolated from Salvia barrelieri, which showed potential antioxidant 
activity. In particular, 7-oxoroyleanone-12-Me ester possessed the highest superoxide 
anion scavenging activity, while inuroyleanol inhibited  lipid peroxidation and showed 
the highest diphenyl-2-picrylhydrazyl (DPPH) scavenging activity [31]. 
An increasing number of quinone diterpenoids are being found in Salvia 
miltiorrhiza, which is used in many therapeutic remedies in Chinese traditional 
medicine. Tanshinones are the major bioactive compounds of this plant and have been 
well-studied for their biological activities. A recent study has shown the anticancer 
activity of tanshinones and this effect is associated with their inhibition of HIF-1 
accumulation [32]. It as been reported that sibiriquinone A, sibiriquinone B, 
cryptotanshinone, and dihydrotanshinone I greatly inhibited hypoxia-induced 
luciferase expression on AGS cells (a human gastric cancer cell line), and on Hep3B 
cells (a human hepatocarcinoma cell line)[32]. Recently, anti-cancer activities of 
tanshinone I have been reported. The effect of tanshinone I on the induction of 
apoptosis in human breast cancer cells (MCF-7 and MDA-MB-231) in vitro has been 
investigated. Tanshinone I inhibited cell proliferation of MCF-7 and MDA-MB-231 
cells in a concentration- and time-dependent manner and significantly induced 
apoptosis in these cells. The induction of apoptotic cell death was mediated by the 
activation of caspase 3, the downregulation of the level of the anti-apoptotic protein 
Bcl-2, and the upregulation of the level of the pro-apoptotic protein Bax [33]. In 
another study, it has been found that tanshinone I concentration dependently inhibited 
ICAM-1 and VCAM-1 expressions in human umbilical vein endothelial cells 
(HUVECs) and pre-treatment with tanshinone I significantly reduced adhesion of 
either monocyte U937 or MDA-MB-231 cells to HUVECs. In addition, tanshinone I 
effectively inhibited TNF-alpha-induced production of vascular endothelial growth 
factor (VEGF) and VEGF-mediated tube formation in HUVECs. Tanshinone I also 
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inhibited TNF-alpha-induced VEGF production in MDA-MB-231 cells and migration 
of MDA-MB-231 cells through extracellular matrix. Additionally, a reduction in 
tumor mass volume and decrease in metastasis incidents by tanshinone I was observed 
in vivo [34]. Another recent study investigated the anticancer effects of tanshinones on 
the highly invasive human lung adenocarcinoma cell line CL1-5. Tanshinone I 
significantly inhibited migration, invasion, and gelatinase activity in macrophage-
conditioned medium-stimulated CL1-5 cells in vitro and reduced the tumorigenesis 
and metastasis in CL1-5-bearing severe combined immunodeficient mice. These 
effects are mediated, at least in part, through transcriptional activity of interleukin-8, 
the angiogenic factor involved in cancer metastasis, Ras-mitogen-activated protein 
kinase, and Rac1 signaling pathways [35]. Unlike tanshinone I, which did not have 
direct cytotoxicity, tanshinone IIA, a diterpene quinone extracted from Salvia 
miltiorrhiza, has been reported to have apoptosis inducing effects on a large variety of 
cancer cells. The anti-proliferation and apoptosis inducing effects of tanshinone IIA as 
well as its influence on cell adhesion to and invasion through the extracellular matrix 
(ECM) on acute promyelocytic leukemia (APL) NB4 cells in vitro were studied. 
Tanshinone IIA exhibited induction of apoptosis by activation of caspase-3, 
downregulation of anti-apoptotic protein bcl-2 and bcl-xl and upregulation of pro-
apoptotic protein bax, as well as disruption of the mitochondrial membrane potential 
[36]. Recently, Liu et al [37] have confirmed the antiproliferation and apoptosis effects 
of tanshinone IIA on leukemia THP-1 cell lines. It is reported that tanshinone IIA 
arrests cancer cells in mitosis by disrupting the mitotic spindle and subsequently 
triggered cells to enter apoptosis through the mitochondria-dependent apoptotic 
pathway. In comparison with other existing anti-cancer drugs that cause mitotic arrest 
by interfering with the microtubule structure (such as vincristine or taxol), tanshinone 
IIA destroyed only the mitotic spindle during the M phase but not the microtubule 
structure in interphase cells [38]. Kim et al [39] have recently shown that tanshinone 
IIA completely inhibited osteoclastogenesis, indicating a correlation between Salvia 
miltiorrrhiza extract-inhibitory effect on osteoporosis and its chemical metabolites.  
Tanshinone IIA also exerts antioxidant and anti-inflammatory actions in many 
experimental diseases: Tanshinone IIA protects cardiac myocytes against oxidative 
stress-triggered damage and apoptosis [40] and reduces macrophage death induced by 
hydrogen peroxide by up regulating glutathione peroxidise [41]. Tanshinone IIA 
decreases the transcription level of the microsomal triglyceride transfer protein gene, 
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suggesting that it inhibits ApoB secretion via a proteasome-dependent pathway [42]. 
Recently, it has also been reported that tanshinone IIA, tanshinone I and 15,16-
dihydrotanshinone, from Salvia miltiorrhiza, enhanced the activity of insulin on the 
tyrosine phosphorylation of the insulin receptor (IR) beta-subunit and the activation of 
the downstream kinases signalling in vitro [43]. It has been demonstrared that 
tanshinone IIA not only inhibits the oxidation but also suppresses the inflammation in 
atherosclerotic lesion [44]. Tanshinone IIA has multiple effects on the inhibition of 
human aortic smooth muscle cell (HASMC) migration and may offer a therapeutic 
approach to block HASMC migration [45]. The effects of tanshinone derivatives 
(tanshinone I, cryptotanshinone, 15,16-dihydrotanshinone I) on prostaglandin (PG) 
and nitric oxide (NO) metabolism have also been reported. Jeon et al 2008[46] have 
recently demonstrated that cyclooxygenase-2 (COX-2)-mediated PGE2 production, 
from lipopolysaccharide-treated RAW 264.7 cells, was inhibited by tanshinone I, 
cryptotanshinone and 15,16-dihydrotanshinone I, while only cryptotanshinone and 
15,16-dihydrotanshinone I inhibited inducible NO synthase (iNOS)-mediated NO 
synthesis. These results prove that cryptotanshinone is a down-regulator of 
proinflammatory molecule expression, including COX-2 and iNOS, and inhibits the 
activation of the transcription factors, such as nuclear transcription factor-kappaB and 
activator protein-1. Moreover, cryptotanshinone exhibits in vivo anti-inflammatory 
activity against carrageenan-induced paw edema in rats [46]. The immunomodulatory 
action of tanshinlactone A, from Salvia miltiorrhiza, has been reported [47]. It has 
been pointed out that tanshinlactone A reduced mitogen-activated protein kinases 
(MAPK) activation and modulated interleukin-2 (IL-2) and interferon-gamma (IFN-
gamma) gene expression.  
The vascular effects of tanshinones have been studied. The most abundant 
lipophilic diterpene quinones obtained from Salvia miltiorrhiza and Salvia przewalskii 
roots, tanshinone IIA and cryptotanshinone, inhibited contraction of the isolated 
porcine coronary artery to the thromboxane A 2 analogue, U46619. Przewaquinone A, 
a lipophilic diterpene quinone that can be found only in Salvia przewalskii, induced a 
similar but greater inhibitory action on vascular contraction than tanshinone IIA and 
cryptotanshinone [48]. Sodium tanshinone II-A sulfonate (DS-201), a water-soluble 
derivative of tanshinone IIA, induced relaxation of the coronary smooth muscle which 
had been contracted with KCl, and the relaxation was inhibited by iberiotoxin (IbTX), 
a specific BK(Ca) channel blocker, indicating that the vasodilatation is related to 
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activation of BK(Ca) [49]. Previous reports have demonstrated that radix Salvia 
miltiorrhiza extract (Danshen) induces the expression of CYP3A in rodents and Yu et 
al [50] have recently shown that tanshinone IIA and cryptotanshinone are able to 
activate the CYP3A promoter by binding at human pregnane X receptors (PXR), a 
family of nuclear receptors.  
The activities on the central nervous system (CNS) of some abietane-quinone-
type diterpenoids have been reported. It is known that tanshinone IIB (primary active 
diterpenoids from the roots of Salvia miltiorrhiza) is widely used in the treatment of 
cardiovascular and central nervous system (CNS) diseases [51]. Tanshinone I, 
tanshinone IIA, cryptotanshinone, and 15, 16-dihydrotanshinone I significantly 
reversed scopolamine-induced cognitive impairments in mice. Tanshinone I and 
tanshinone IIA  also reversed diazepam-induced cognitive dysfunctions. In addition, 
cryptotanshinone and 15, 16-dihydrotanshinone I were found to have an inhibitory 
effect on acetylcholinesterase (AChE) in vitro [52]. Cryptotanshinone also modulates 
amyloid precursor protein metabolism and attenuates beta-amyloid deposition through 
upregulating alpha-secretase in vivo and in vitro [53].  
 
 
               Figure 2: abietane phenolic-type diterpenoids from Salvia species. 
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Figure 3: abietane quinone-typr diterpenoids from Salvia species. 
 
Among abietane-type diterpenoids from Salvia species, some compounds with 
icetexane skeleton were found. Lanigerol, from Salvia lanigera [54] and brussonol, 
from Salvia broussonetii [55] are an example. 5-epi-icetexone, from Salvia gilliessi, 
was found to exert an antiproliferative effect on cultured epimastigotes of 
Trypanosoma cruzi (Tulahuen) [56]. New two-icetaxane diterpene, fruticuline A and 
demethylfruticuline A, were obtained from Salvia corrugata. Demethylfruticuline A 
was shown to be highly bactericidal against Staphylococcus aureus and S. epidermidis 
and bacteriostatic against Enterococcus faecalis and E. faecium. Fruticuline A 
manifested bacteriostatic activity against all tested strains [57]. Another group of tri-
cyclic diterpenoids is of pimarane-type. From the aerial parts of Salvia cinnabarina a 
diterpenoid with pimarane skeleton, the compound 3,4-secoisopimar-4(18),7,15-
triene-3-oic acid was isolated [58]. Further studies have shown that 3,4-secoisopimar-
4(18),7,15-triene-3-oic acid reduced intestinal motility in vivo [59], the urinary 
bladder contractility in vitro [60], both with a mechanism involving calcium channel. 
It possessed a weak hypotensive activity in vitro [61] and has pronounced CNS 
depressant properties manifested as sedation and axiolitic effects in vivo [62]. 
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Isopimaric acid and two new derivates characterised as 14-!-hydroxy-isopimaric acid, 
3-"-hydroxy-isopimaric acid from Salvia jamensis, have been reported to have platelet 
antiaggregating activity in vitro [63].  
 
 
 
Figure 4: abietane icetaxane-type diterpenoids from Salvia species. 
 
 
 
Figure 5: pimarane-type diterpenoids from Salvia species. 
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Table B: Tri-cyclic diterpenoids isolated from Salvia species and their biological activies 
 
Tri-cyclic 
diterpenoids 
Secondary metabolite 
constituents 
 
Salvia species Biological activities 
• carnosic acid and carnosol 
 
Salvia 
officinalis,  
Salvia cilicica,  
Salvia africana-
lutea 
 
• antioxidant, anti-
inflammatory effects by 
antagonism of intracellular 
Ca(2+) mobilisation 
induced by a chemotactic 
stimulus 
 
• attenuate formation of 
reactive oxygen species 
and the secretion of human 
leukocyte elastase 
 
• antimicrobial activity 
 
• carnosic acid 12-Me ester 
 
Salvia 
microphylla 
• antimicrobial activity 
 
• ferruginol 
 
Salvia sclarea 
 
• antibacterial activity 
 
 
 
Abietane- 
Phenolic type 
• 7-methoxyrosmanol and 
galdosol 
Salvia 
officinalis 
• binding activity to the 
benzodiazepine receptor 
 
• aethiopinone, salvipisone 
• and 1-oxoaethiopinone  
 
Salvia sclarea 
 
• bacteriostatic as well as 
bactericidal for the 
cultures of S. aureus and S. 
epidermidis 
 
• showed synergy activity 
with %-lactam antibiotics 
 
• yunnannin A and 
danshenol C 
Salvia 
yunnanensis 
 
• antitumor activity in T-24, 
QGY, K562, Me180 and 
BIU87 cell lines 
 
• 7-oxoroyleanone-12-Me 
ester and inuroyleanol 
Salvia 
barrelieri 
• showed potential 
antioxidant activity. 
• sibiriquinone A and 
sibiriquinone B 
 
Salvia 
miltiorrhiza 
 
• antitumor activity in human 
gastric cancer and human 
hepatocarcinoma cell lines 
 
 
 
Abietane- 
Quinone type 
• 15,16-dihydrotanshinone I Salvia 
miltiorrhiza 
 
• antitumor activity in human 
gastric cancer and human 
hepatocarcinoma cell lines 
 
• inhibits cyclooxygenase-2 
(COX-2)-mediated PGE2 
production and inducible 
NO synthase (iNOS)-
mediated NO synthesis 
 
• inhibits the activation of the 
transcription factors, such 
as nuclear transcription 
factor-kappaB and 
activator protein-1  
 
• inhibitory effect on 
acetylcholinesterase 
(AChE) in vitro 
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• reverses scopolamine-
induced cognitive 
impairments in mice 
 
• enhances the activity of 
insulin on the tyrosine 
phosphorylation of the 
insulin receptor (IR) beta-
subunit and the activation 
of the downstream kinases 
signalling in vitro 
 
• cryptotanshinone  
 
Salvia 
miltiorrhiza 
 
• antitumor activity in human 
gastric cancer and human 
hepatocarcinoma cell lines 
 
• inhibits cyclooxygenase-2 
(COX-2)-mediated PGE2 
production and inducible 
NO synthase (iNOS)-
mediated NO synthesis 
 
• inhibits the activation of the 
transcription factors, such 
as nuclear transcription 
factor-kappaB and 
activator protein-1  
 
• exhibits in vivo anti-
inflammatory activity 
against carrageenan-
induced paw edema in rats  
 
• inhibits contraction of the 
isolated porcine coronary 
artery to the thromboxane 
A 2 analogue, U46619 
 
• reverses scopolamine-
induced cognitive 
impairments in mice 
 
• inhibitory effect on 
acetylcholinesterase 
(AChE) in vitro 
 
• modulates amyloid 
precursor protein 
metabolism and attenuates 
beta-amyloid deposition 
through upregulating 
alpha-secretase in vivo and 
in vitro 
 
• is able to activate the 
CYP3A promoter by 
binding at human pregnane 
X receptors (PXR), a 
family of nuclear 
receptors. 
 
• przewaquinone A 
 
Salvia 
przewalskii  
 
• inhibitory action on 
vascular contraction  
 
 
• tanshinlactone A  Salvia 
miltiorrhiza 
• immunomodulatory action 
by mitogen-activated 
protein kinases (MAPK) 
activation and interleukin-2 
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(IL-2) and interferon-
gamma (IFN-gamma) gene 
expression 
 
• tanshinone I 
 
Salvia 
miltiorrhiza 
 
• antiproliferation activity in 
human breast cancer cells, 
MCF-7 and MDA-MB-231 
cells, through the 
regulation of apoptotic 
pathway  
 
• inhibits TNF-alpha-induced 
production of vascular 
endothelial growth factor 
(VEGF) 
 
• reduces the tumorigenesis 
and metastasis in CL1-5, 
the highly invasive human 
lung adenocarcinoma cell 
line, through transcriptional 
activity of interleukin-8, 
the angiogenic factor 
involved in cancer 
metastasis, Ras-mitogen-
activated protein kinase, 
and Rac1 signaling 
pathways 
 
• inhibits cyclooxygenase-2 
(COX-2)-mediated PGE2 
production 
 
• reverses scopolamine-
induced cognitive 
impairments in mice and 
diazepam-induced 
cognitive dysfunctions 
 
 
• tanshinone IIA 
 
Salvia 
miltiorrhiza 
 
• anti-proliferation and 
apoptosis activity on acute 
promyelocytic leukemia 
(APL) NB4 cells, by 
regulation of anti- and pro-
apoptotic protein, as well 
as disruption of the 
mitochondrial membrane 
potential 
 
• causes mitotic arrest by 
interfering with the 
microtubule structure (such 
as vincristine or taxol) and 
destroying only the mitotic 
spindle during the M phase 
but not the microtubule 
structure in interphase cells 
 
• inhibited osteoclastogenesis 
 
• protects cardiac myocytes 
against oxidative stress-
triggered damage and 
apoptosis and 
• reduces macrophage death 
induced by hydrogen 
peroxide by up regulating 
glutathione peroxidise 
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• inhibits ApoB secretion via 
a proteasome-dependent 
pathway 
 
• enhances the activity of 
insulin on the tyrosine 
phosphorylation of the 
insulin receptor (IR) beta-
subunit and the activation 
of the downstream kinases 
signalling in vitro 
 
• suppresses the 
inflammation in 
atherosclerotic lesion 
inhibits migration of human 
aortic smooth muscle cell 
(HASMC) 
 
• reverses scopolamine-
induced cognitive 
impairments in mice and 
diazepam-induced 
cognitive dysfunctions 
 
• inhibits contraction of the 
isolated porcine coronary 
artery to the thromboxane 
A 2 analogue, U46619 
 
• is able to activate the 
CYP3A promoter by 
binding at human pregnane 
X receptors (PXR), a 
family of nuclear 
receptors. 
 
• tanshinone IIB Salvia 
miltiorrhiza 
 
• is widely used in treatment 
of cardiovascular and 
central nervous system 
(CNS) diseases 
 
 
 
• sodium tanshinone II-A 
sulfonate  
 
Salvia 
miltiorrhiza 
 
• induced relaxation of the 
coronary smooth muscle 
and the vasodilatation is 
related to activation of 
BK(Ca) 
 
• lanigerol 
 
Salvia lanigera   
• brussonol 
 
Salvia 
broussonetii 
 
• 5-epi-icetexone 
 
Salvia gilliessi  
 
 
• antiproliferative effect on 
cultured epimastigotes of 
Trypanosoma cruzi 
 
• fruticuline A  
 
Salvia 
corrugata 
 
• bacteriostatic activity 
 
 
 
Abietane- 
Icetaxane type 
• demethylfruticuline A Salvia 
corrugata 
 
• bactericidal against 
Staphylococcus aureus and 
S. epidermidis and 
bacteriostatic against 
Enterococcus faecalis and 
E. faecium 
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• 3,4-secoisopimar-
4(18),7,15-triene-3-oic 
acid 
 
Salvia 
cinnabarina 
 
• reduces intestinal motility 
in vivo and the urinary 
bladder contractility in 
vitro  
 
• weak hypotensive activity 
in vitro 
 
• CNS depressant properties 
manifested as sedation and 
axiolitic effects in vivo 
 
 
 
Pimarane-type 
• isopimaric acid, 14-!-
hydroxy-isopimaric acid, 
3-"-hydroxy-isopimaric 
acid 
Salvia jamensis • platelet antiaggregating 
activity in vitro 
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Triterpenoids from Salvia species  
Triterpenoids, resulting from the combination of 6 isoprene units, are classified 
as oleanane, ursane, lupane, dammarane-type (table C). Many bioactive triterpenoids 
from Salvia species have been documented [3]. Oleanolic acid and ursolic acid, 
isolated from Salvia officinalis, showed antimicrobial activity against vancomycin-
resistant enterococci, Streptococcus pneumoniae, and methicillin-resistant 
Staphylococcus aureus [26]. Ursolic acid, obtained from Salvia miltiorrhiza, 
upregulates eNOS and downregulates Nox4 expression in human endothelial cells 
[64]. Antiprotease and antimetastatic activity in vitro of beta-ursolic acid isolated from 
Salvia officinalis was also investigated [65]. It has been reported that beta-ursolic acid 
shows the strongest inhibition activity to urokinase, serine proteases, and cathepsin B, 
the cysteine protease. These interesting results have indicated a possible anticancer 
effect of beta-ursolic acid. Therefore, it is reported that beta-ursolic acid inhibits lung 
colonization of beta16 mouse melanoma cells in vivo [65].  
Lupeol, a lupane-type triterpene, has been shown to possess many 
pharmacological properties including anticancer effects. Lupeol novel antiproliferative 
and apoptotic potential against prostate cancer has been reported [66]. Lupeol 
treatment of highly aggressive human metastatic melanoma cells caused G(1)-S phase 
cell cycle arrest and apoptosis: It is a downregulator of Bcl2 and upregulator of Bax. 
Lupeol induced the activation of caspase-3 and the cleavage of poly(ADP)ribose 
polymerase, decreased expression of cyclin D1, cyclin D2, and cdk2; and increased 
expression of p21 protein [67]. 
A recent study reports that lupeol attenuates the characteristics of the 
alterations of allergic airway inflammation in a murine model. Administration of 
lupeol, in the treatment of bronchial asthma in BALB/c mice immunized with 
ovalbumin, caused the reduction of cellularity and eosinophils in the bronchoalveolar 
lavage fluid. Treatment with lupeol also reduced the production of mucus and overall 
inflammation in the lung, and the levels of Type II cytokines IL-4, IL-5 and IL-13 
[68].  
Triterpenes also possess cardioprotective effects, which will be beneficial in 
hypercholesterolemic condition. Lupeol, and its ester lupeol linoleate effects on lipid 
status and biochemical changes on heart tissue, have been studied on male albino 
Wistar rats that were fed with high-cholesterol diet. Authors report that triterpenes 
treatment reduced the above alterations in hypercholesterolemic rats. The 
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transmembrane enzymes, namely Na(+), K(+)-ATPase, Ca(2+)-ATPase and Mg(2+)-
ATPase showed a decrease in their activities. Triterpenes treatment reversed these 
levels, prevented hypertrophic cardiac histology and restored the normal ultrastructural 
architecture [69]. 
In recent studies, lupane-type triterpenoids were investigated for their CNS 
effects. The acetone, ethanol, butanol and water extracts of the aerial parts of Salvia 
sclareoides were screened for in vitro inhibitory activity of acetylcholinesterase 
(AChE) and butyrilcholinesterase (BChE), enzymes that play a role in  Alzheimer’s 
disease. All extracts inhibited acetylcholinesterase activity, a notable effect, since the 
standard drug rivastigmine does not inhibit acetylcholinesterase at the same 
concentration. With regards to butyrilcholinesterase, the acetone extract, where a new 
lupene triterpenetriol was isolated and characterised as (1beta,3beta)-lup-20(29)-ene-
1,3,30-triol, was able to completely inhibit  enzyme activity and the butanol and 
ethanol extracts produced a potent inhibition of BchE [70]. Lupeol, betulin and 
betulinic acid may also interact with the brain neurotransmitter gamma-amino butyric 
acid (GABA) receptors in vitro and in vivo [71].
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Table C: Triterpenoids isolated from Salvia species and their biological activities 
 
 
 
 
 
 
Triterpenoids Secondary metabolite 
constituents 
 
Salvia species Biological activities 
 
Oleanane-type 
• oleanolic acid Salvia 
officinalis 
• antimicrobial activity against 
vancomycin-resistant enterococci, 
Streptococcus pneumoniae, and 
methicillin-resistant Staphylococcus 
aureus 
 
• ursolic acid Salvia 
officinalis  
Salvia 
miltiorrhiza 
Salvia 
jamensis 
• antimicrobial activity against 
vancomycin-resistant enterococci, 
Streptococcus pneumoniae, and 
methicillin-resistant Staphylococcus 
aureus 
 
• upregulates eNOS and 
downregulates Nox4 expression in 
human endothelial cells 
 
 
 
Ursane-type 
• beta-ursolic acid Salvia 
officinalis 
 
• antiprotease and antimetastatic 
activity in vitro 
• lupeol Salvia 
sclareoides 
• causes G(1)-S phase cell cycle 
arrest and apoptosis in human 
metastatic melanoma cells 
 
• attenuates the characteristics of the 
alterations of allergic airway 
inflammation in a murine model 
 
• reduces the alterations produced in 
hypercholesterolemic rats 
 
• in vitro inhibitory activity of 
acetylcholinesterase (AChE) and 
butyrilcholinesterase (BChE) 
 
• interacts with the brain 
neurotransmitter gamma-
aminobutyric acid (GABA) 
receptors in vitro and in vivo 
 
• (1beta,3beta)-lup-
20(29)-ene-1,3,30-
triol 
 • is able to inhibit completely the 
butyrilcholinesterase (BChE) 
activity 
 
 
 
Lupane-type 
• betulinic acid 
 
Salvia 
jamensis 
• interact with the brain 
neurotransmitter gamma- 
aminobutyric acid (GABA) 
receptors in vitro and in vivo 
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CHAPTER 1 
 
The hallucinogenic herb Salvia divinorum and its active ingredient 
salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. 
 
 
Salvia divinorum (figure 1.1) 
belongs to the family Labiatae 
(Lamiaceae), commonly referred to as 
the mint family. Shamanic healers from 
the Mazatec region in Oaxaca, Mexico, 
traditionally use the psychoactive herb 
by chewing fresh leaves or by drinking 
the juice of its leaves [1-3]. It has also 
been used traditionally as a medicine 
for the treatment of a number of 
diseases including headache, 
rheumatism, abdominal swelling and 
diarrhea [1, 4]. More recently, there 
have been reports of using Salvia 
divinorum recreationally for its 
hallucinogenic effects. Salvia 
divinorum leaf preparations or 
concentrated extracts are indeed widely 
available in western Europe and the 
USA, notably on Internet sites, [5] and 
are also used as a marijuana substitute 
[6, 7]. The hallucinatory effect 
produced has been reported to be 
potent and intense, lasting for up to an 
hour when smoked [6, 8]. Although it 
is an emerging intoxicant in the USA 
and Europe [9] very little 
pharmacological research has been 
conducted on this plant. The main 
active constituent of Salvia divinorum 
is salvinorin A (figure 1.2), a 
neoclerodane diterpene. 
 
 
 
 
Figure 1.1: Salvia divinorum 
 
Salvinorin A represents the only 
known hallucinogenic terpenoid and 
has been reported to be the most potent 
naturally occurring hallucinogen, with 
an effective dose, when smoked, of 
0.2–1 mg in humans [7]. Salvinorin A 
induces an intense, short-lived 
hallucinogenic experience qualitatively 
distinct from that induced by  classical 
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hallucinogens such as lysergic acid 
diethylamide (LSD), psilocybin and 
mescaline [7]. Quite recently, it has 
been reported that salvinorin A has 
high affinity and selectivity for the 
cloned !-opioid receptor [10]. Indeed, 
it has been suggested, that salvinorin A 
is a !-opioid receptor agonist [10–13], 
although there is no definitive evidence 
that hallucinations are mediated by !-
opioid receptors. However, the effects 
of salvinorin A on neural functions are 
largely unexplored. As a result of 
anecdotal reports that extracts of Salvia 
divinorum may possess antidiarrhoeal 
activity and because !-opioid receptors 
may modulate intestinal peristalsis [14, 
15]  the effect of Salvia divinorum, and 
its main active ingredient, salvinorin A, 
on myenteric cholinergic transmission 
was investigated. For this purpose  the 
effect of a standardized extract from 
Salvia divinorum leaves (SDE) and of 
isolated salvinorin A on the 
contractions elicited either by electrical 
stimulation or by exogenous 
acetylcholine in the guinea-pig ileum 
were evaluated. 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1,2: Salvinorin A 
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1.1 MATERIAL AND METHODS 
 
1.1.1 Animal 
Male guinea-pigs weighing between 250 and 350 g were purchased from 
Harlan Italy (S. Pietro al Natisone, UD, Italy), and were maintained under controlled 
conditions of temperature (24 ± 2 °C) and humidity (60%) until used. The guinea-pigs 
had free access to water and food. All experiments complied with the Italian D.L. no. 
116 of 27 January 1992 and associated guidelines in the European Communities 
Council Directive of 24 November 1986 (86/609/ECC).  
1.1.2 Tissues and treatment procedure 
Guinea-pigs were killed by asphyxiation with CO2 and segments (1–1.5 cm) of 
the distal ileum lying 5– 15 cm proximal to the ileocaecal valve were quickly removed 
and flushed of luminal contents and placed in Krebs solution (mmol L-1: NaCl 119, 
KCl 4.75, KH2PO4 1.2, NaHCO3 25, CaCl2 2.5, MgSO4 1.5 and glucose 11). 
The segments were set up (in such a way  as to record contractions mainly 
from the longitudinal axis) in an organ bath containing Krebs (20 mL) equilibrated 
with 95%O2, 5%CO2 at 37°C. The tissues were connected to an isotonic transducer 
(load 0.5 g) connected to PowerLab system (Ugo Basile, Comerio, Italy). After a 
minimal 1 h equilibration period, the strips were subjected to electrical field 
stimulation (EFS, 2.5 Hz for 1 s, 400 mA, 1 ms pulse duration), delivered through 
electrodes placed around the tissue. Stable and reproducible contractions for a time 
period of 4 h were obtained with stimulation every 20 s. Contractions were expressed 
as % of contractions produced by 10-5 mol L-1 carbachol; this concentration of 
carbachol produced a maximal contractile effect (100% contraction). After stable 
control contractions evoked by EFS had been recorded, the contractile responses were 
observed in the presence of increasing cumulative concentrations of SDE (0.01–300 
ng mL-1). The contact time for each concentration was 10 min.  
Preliminary experiments showed that this contact time was sufficient for SDE to 
achieve maximal effect. The effect of SDE was also evaluated after the administration 
in the bath (contact time 30 min) of NG-nitro-L-arginine methyl ester (L-NAME, 3x10-
4 mol L-1) (to block NO synthesis), apamin (10-7 mol L-1) (a blocker of Ca2+-activated 
K+ channels which blocks the enteric inhibitory component mediated by ATP or a 
related purine), yohimbine (10-7 mol L-1) (to block a2-adrenergic receptors), 
thioperamide (10-6 mol L-1) (to block H3 receptors), methysergide (10-6 mol L-1) [to 
 
34 
block 5- hydroxytryptamine (5-HT) receptors], naloxone (10-6 mol L-1) (to block 
opioid receptors), naltrindole (3x10-8 mol L-1) (to block $-opioid receptors), CTOP 
(10-6 mol L-1) (to block µ-opioid receptors) and norbinaltorphimine (3x10-8 mol L-1) 
(to block !-opioid receptors). In preliminary experiments the effect of tetrodotoxin 
(3x10-7 mol L-1) or atropine (10-6 mol L-1) (contact time 10 min) on EFS-induced 
contractions was evaluated. These concentrations were selected on the basis of 
previous work. [15–18] The effect of SDE was also evaluated (contact time 10 min) 
on the contractions produced by exogenous acetylcholine (10-6 mol L-1). This 
concentration of acetylcholine gave a contractile response that was similar in 
amplitude to that of electrical stimulation. Acetylcholine was left in contact with the 
tissue for 60 s and then washed out. The interval between each contraction was 10 
min. In another set of experiments, the effect of salvinorin A (10-12–10-6 mol L-1), the 
!-opioid antagonist U- 50488 (10-12–10-6 mol L-1) or SDE without salvinorin A (1–100 
000 ng mL-1) on EFS- or acetylcholine-induced contractions was also evaluated 
(contact time: 10 min for each concentration). Salvinorin A was also evaluated in the 
presence of naloxone (10-6 mol L-1), naltrindole (3x10-8 mol L-1), CTOP (10-6 mol L-1) 
and nor-binaltorphimine (3x10-8 mol L-1). 
1.1.3 Drugs  
An ethanolic extract (320 g) from dried Salvia divinorum leaves (2 kg) was 
prepared and a portion of this extract (20 g) was standardized to contain 1.6% 
salvinorin A (SDE) or the equivalent to 0.3% salvinorin A from dried leaves. Briefly, 
the extract was separated by reverse phase C18 vacuum liquid chromatography (VLC) 
eluted in a gradient manner using methanol: water (70: 30–100: 0) until no color was 
observed in the fractions. The fractions containing salvinorin A were combined and all 
VLC fractions and washings, with the exception of the salvinorin A fractions, were 
recombined and evaporated to dryness to give an extract without salvinorin A (263 g). 
The salvinorin A from the crystallizations and column fractions was purified by 
solvent/solvent partitions (aqueous methanol: hexanes) and recrystallizations (95% 
ethanol). A 1.6% standardized extract was made from the purified salvinorin A (333 
mg) and the extract without salvinorin A (19.78 g). Acetylcholine hydrochloride, 
carbachol chloride, apamin, yohimbine hydrochloride, methysergide, L-NAME 
hydrochloride, thioperamide, U-50488, naloxone hydrochloride, tetrodotoxin, were 
purchased from Sigma (Milan, Italy). Naltrindole, CTOP and nor-binaltorphimine 
were purchased from Tocris Cookson (Avonmouth, UK). Salvinorin A, naltrindole, 
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CTOP, nor-binaltorphimine, tetrodotoxin and thioperamide were dissolved in dimethyl 
sulphoxide (DMSO). SDE and SDE without salvinorin A were dissolved in DMSO 
(stock solution: 1 mg mL-1 and 100 mg mL-1, respectively) and then diluted in distilled 
water for the lower concentrations. The other drugs were dissolved in distilled water. 
DMSO (<0.01%) did not modify EFS-induced contractions. 
1.1.4 Data analysis and statistics 
Results are expressed as mean ± SEM. Nonlinear regression analysis for all 
concentration response curves were performed (Graph Pad Instat program version 
4.01; GraphPad Software, Inc., San Diego, CA, USA). Data were analysed by Two-
way ANOVA. A value of P < 0.05 was considered significant. The concentrations of 
SDE, SDE without salvinorin A, salvinorin A or U-50488 that produced 50% 
inhibition of EFS-induced contractions (IC50) or maximal effect (Emax) were used to 
characterize their potency and efficacy respectively. The IC50 and Emax values 
[geometric mean ± 95% confidence limits (CL)] were calculated using the Graph Pad 
Instat program version 4.01. 
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1.2 RESULTS 
 
1.2.1 EFS-induced contractions: effect of various antagonists or inhibitors  
The EFS (2.5 Hz for 1 s, 400 mA, 0.25 ms pulse duration) of the guinea-pig 
ileum evoked a contractile response that was 49 ± 5% of the contraction produced by 
10-4 carbachol (n=7). These EFS-induced contractions were abolished by tetrodotoxin 
(3x10-7 mol L-1) or atropine (10-6 mol L-1), thus indicating that these contractions were 
due to the release of acetylcholine from enteric nerves. EFS-induced contractions were 
not significantly modified by naloxone (10-6 mol L-1)(5 ± 3% increase), yohimbine(10-
7 mol L-1)(6 ± 4% increase), L-NAME (3x10-4 mol L-1) (22 ± 5% increase), 
thioperamide (10-6 mol L-1) (4 ± 5% increase), naltrindole (3x10-8 mol L-1) (12 ± 4% 
increase), CTOP (10-6 mol L-1) (10 ± 5% increase), (n =7–8 experiments for each 
antagonist used). By contrast, nor-binaltorphimine (3x10-8 mol L-1) and apamin (10-7 
mol L-1) significantly increased EFS-induced contractions (36 ± 5% and 46 ± 4% 
increase, respectively, P < 0.05, n=7–8 experiment for both compounds). 
Methysergide (10-6 mol L-1) produced a transient contractile effect, but did not modify 
EFS-induced contractions after 30-min contact (data not shown).  
1.2.2 EFS-induced contractions: effect of SDE or salvinorin A 
The SDE (0.01–300 ng mL-1) as well as SDE without salvinorin A (3–100 000 
ng mL-1) decreased, in a concentration- dependent manner, the amplitude of EFS 
evoked contractions (figure 1.3). Statistical significance was achieved starting from 
the 3 ng mL-1 concentration (SDE) and 10 000 ng mL-1 concentrations. The IC50 (95% 
CL) values were 1.72 ng mL-1 (0.93–3.1) for SDE and 7504 ng mL-1 (5406–1042) for 
SDE without salvinorin A. The Emax (95% CL) values were 55.89% (48.89–62.88) for 
SDE and 59.67% (52.19–67.16)% for SDE without salvinorin A. Figure 1.4 shows the 
effect of SDE on EFS-evoked contractions in the presence of drugs that block main 
prejunctional receptors (i.e. opioid, a2-adrenergic and histamine H3 receptors) (figure 
1.4 panel A), or in the presence of selective opioid receptor antagonists (figure 1.4 
panel B), and in the presence of drugs that block the enteric inhibitory transmission 
(i.e. L-NAME and apamin) (figure1.4 panel C). Naloxone and nor-binaltorphimine, 
but not the other drugs, counteracted the inhibitory effect of SDE on EFS-induced 
contractions. Moreover, the inhibitory effect of SDE on EFS-induced contractions was 
not modified by methysergide [(% variation, SDE): 0.01 ng mL-1: 1.1 ± 1; 0.03 ng mL-
1: 1.90 ± 1; 0.1 ng mL-1:2.61 ± 2; 0.3 ng mL-1: 4.98 ± 3; 1 ng mL-1: 21.24 ± 4; 3 ng 
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mL-1: 36.49 ± 5; 10 ngmL-1: 53.07 ± 4; 30 ng mL-1: 54.13 ± 5; 100 ng mL-1: 55.13±4; 
300 ng mL-1 :55.52 ± 5; (% variation, SDE + methysergide) 0.01 ng mL-1: 1.5 ± 4; 
0.03 ng mL-1: 2.0±4; 0.1 ng mL-1: 3.0 ± 4; 0.3 ng mL-1: 5.10 ± 5; 1 ng mL-1: 20.04 ± 4; 
3 ng mL-1: 31.63 ± 6; 10 ng mL-1: 49.50 ± 5; 30 ng mL-1: 50.82 ± 5; 100 ng mL-1: 
52.64±4; 300 ng mL-1: 55.91 ± 5; n = 7–8]. 
 
 
 
 
Figure 1.3: Effect of Salvia divinorum extract (SDE) with or without salvinorin A on the contractile 
response produced by electrical field stimulation (EFS) in the isolated guinea-pig ileum. Each point represents the 
mean of 7 – 8 experiments. Vertical lines show SEM *P < 0.05 and **P < 0.01 vs corresponding control. 
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Figure 1.4: Electrical field stimulation 
(EFS)-induced contractions in the isolated guinea-pig 
ileum: Effect of Salvia divinorum extract (SDE; 0.01–
300 ng mL-1) alone (vehicle) or in presence of 
yohimbine (10-6 mol L-1), naloxone (10-6 mol L-1), 
thioperamide (10-6 mol L-1) (A), naltrindole (3x10-8 
mol L-1), CTOP (10-6 mol L-1), nor-binaltorphimine 
(3x10-8 mol L-1) (B), NG-nitro-L-arginine methyl ester 
(LNAME, 3x10-4 mol L-1) or apamin (10-7 mol L-1) 
(C). Each point represents the mean of 7–8 
experiments. Vertical lines show SEM. ***P < 0.001 
vs vehicle (significance between curves). 
 
 
 
The effect of salvinorin A, the main psychoactive compound in Salvia 
divinorum, on EFS-induced contractions is shown in figure 1.5. Salvinorin A (10-12– 
10-6 mol L-1) decreased, in a concentration-dependent manner, the amplitude of EFS-
evoked contractions [IC50 (95% CL): 3.9x10-9 mol L-1 (8.40x10-10– 1.48x10-8); Emax 
(95% CL): 68.12 (50.62–87.28) %]. The inhibitory effect of salvinorin A was 
counteracted by naloxone and nor-binaltorphimine, but not by CTOP or naltrindole. 
The selective j-opioid receptor agonist U-50488, used as a reference compound, also 
inhibited EFS-induced contractions [(IC50 (95% CL): 1.86x10-9 mol L-1 (1.48x10-9–
2.23x10-9); Emax (95% CL): 51.32% (49.47–53.18)]. 
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Figure 1.5: Electrical field stimulation 
(EFS)-induced contractions in the isolated guinea-
pig ileum: effect of salvinorin A (10-12-10-6 mol L-1) 
(vehicle) alone or in presence of naloxone (10-6 mol 
L-1), of naltrindole (3x10-8 mol L-1), of CTOP (10-6 
mol L-1) and of nor-binaltorphimine (3x10-8 mol L-
1). Each point represents the mean of 7–8 
experiments. Vertical lines show SEM. ***P < 
0.001 vs vehicle (i.e. the naloxone and nor-
binaltorphimine concentration–response curves were 
significantly different from the vehicle curve). 
 
  
1.2.3 Acetylcholine-induced contractions: effect of SDE or salvinorin A 
When the ileum was stimulated with exogenous acetylcholine (10-6 mol L-1), 
both SDE and salvinorin A were without effect [(% inhibition): SDE 0.01 ng mL-1: 1.8 
± 4; SDE 0.03 ng mL-1: 2.3 ± 5; SDE 0.1 ng mL-1: 4.0 ± 4; SDE 0.3 ng mL-1: 8.10 ± 5; 
SDE 1 ng mL-1: 6.04 ± 4; SDE 3 ng mL-1: 8.53 ± 5; SDE 10 ng mL -1: 8.53 ± 4; SDE 
30 ng mL-1: 9.02 ± 5; SDE 100 ng mL-1: 7.74 ± 4; SDE 300 ng mL-1: 8.71 ± 5, P > 
0.05, n ) 7–8; salvinorin A 10-12 mol L-1: 0.8 ± 4; salvinorin A 10-11 mol L-1: 1.3 ± 
4; salvinorin A 10-10 mol L-1: 5.0 ± 5; salvinorin A 10-9 mol L-1: 6.50 ± 5; salvinorin A 
10-8 mol L-1: 8.04 ± 5; salvinorin A 10 -7 mol L-1: 7.53 ± 5; salvinorin A 10-6 mol L-1: 
8.0 ± 4; P > 0.05, n=7–8]. At the higher concentrations tested neither SDE (300 ng 
mL-1) nor salvinorin A (10-6 mol L-1) significantly modified the concentration–
response curve to acetylcholine (10-8– 10-4 mol L-1) (data not shown). 
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1.3 DISCUSSION 
 
Salvia divinorum is a hallucinogenic sage that has been gaining recreational 
popularity. Although traditionally the herb is mainly used for its psychoactive effects, 
it is also reportedly used to treat a variety of disorders, including those affecting the 
digestive tract (e.g. abdominal swelling and diarrhoea) [1, 19]. However, the potential 
pharmacological activities of this plant related to the central and peripheral nervous 
system are largely under-researched. In the present study it is shown that SDE, as well 
as its main active ingredient salvinorin A, inhibited enteric cholinergic transmission in 
the guinea-pig ileum. These results could provide the pharmacological basis 
underlying its traditional antidiarrhoeal use. It is shown that SDE inhibited the 
contractions induced by EFS in the guinea-pig ileum, which are mediated by the 
release of acetylcholine from myenteric nerves. Moreover, when the ileum was 
exposed to SDE at concentrations that markedly inhibited the twitch response, the 
contractile response to exogenous acetylcholine (which is mediated by activation of 
postjunctional muscarinic receptors) remained unchanged. These observations strongly 
support the hypothesis that SDE inhibits the twitch response by acting prejunctionally 
rather than through a direct action on intestinal smooth muscle. Consequently, the 
mechanism(s) underlying the inhibition of neural function by SDE was/were 
investigated. 
It is well known that opioid peptides exert inhibitory effects on gastrointestinal motor 
function [20]. Opioid agonists inhibit acetylcholine release from myenteric neurones 
and attenuate twitch contraction of the longitudinal muscle in response to transmural 
electrical stimulation [21]. Immunohistochemical studies have revealed that the opioid 
receptor subtypes µ, $ and ! are present in neural tissues of the guinea-pig enteric 
nervous system, but not in smooth cells,[22] and their activation results in inhibition of 
enteric cholinergic transmission [22]. In the present study  strong evidence is provided 
that the inhibitory effect of SDE is mediated by !-opioid receptors. Indeed the 
inhibitory effect of SDE on electrically evoked contractions was abolished by the non-
selective opioid antagonist naloxone and the selective !-opioid antagonist nor-
binaltrophimine, but not by the µ-opioid antagonist CTOP or by the $-opioid 
antagonist naltrindole. These experiments make it possible to exclude a number of 
factors as potential contributory mechanisms involved in the inhibition of cholinergic 
transmission by SDE. In particular what may be excluded is the involvement of (a) 
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other prejunctional systems (i.e. histamine H3 and #2- adrenergic receptors) negatively 
coupled to cholinergic transmission as the inhibitory effect of SDE was not affected by 
#2-adrenergic receptor antagonist yohimbine or by the histamine H3 receptor 
antagonist thioperamide; (b) enteric inhibitory nerves as apamin (a blocker of Ca2+ 
activated K+ channels which blocks the enteric inhibitory component mediated by 
ATP or related purine [23]) or L-NAME (an inhibitor of NO synthase) did not modify 
the inhibitory effect of SDE on twitch response; (c) 5-HT receptors as the depressant 
effect of SDE was insensitive to the 5-HT receptor antagonist methysergide. The lack 
of involvement of 5-HT receptors is relevant in the light of the observation that 5-
HT2A receptors represent the primary molecular target responsible for the actions of 
classic hallucinogens such as LSD, psilocybin and mescaline [24, 25]. Salvia 
divinorum contains numerous biologically active constituents, including salvinorins, 
divinatorins and hardwickiic acid. [2] Salvinorin A is believed to be the compound 
responsible for the hallucinogen properties of Salvia divinorum. Salvinorin A has been 
reported to be the most potent naturally occurring hallucinogen, with an effective dose, 
when smoked, of 200–1000 g in humans [7, 8]. In the present study  strong evidence is 
provided that the pharmacological activity of SDE on myenteric nerves observed here 
is mainly the result of salvinorin A content. Indeed, extracts of SDE without salvinorin 
A were approximately 4500-fold less active than the same extract with salvinorin A, 
and salvinorin A itself inhibited myenteric cholinergic transmission. Moreover, the 
main findings reported for SDE were confirmed with salvinorin A. In particular, it was 
found that salvinorin A: (a) inhibited electrically evoked contractions without affecting 
the contractions induced by exogenous acetylcholine (which is consistent with a 
prejunctional site of action); (b) exerted this inhibitory effect possibly through 
activation of !-opioid receptors, as the inhibitory effect of this compound (as well as 
of the !-opioid agonist U-50488, used as a reference compound) on electrically 
induced contractions was abolished by the non-selective opioid antagonist naloxone as 
well as by the selective !-opioid antagonist nor-binaltrophimine. Consistent with these 
results, it has been shown that salvinorin A has been found to be a potent agonist of 
the human !-opioid receptor expressed in human embryonic kidney 293 (HEK293) 
cells with an EC50 of 1.05 nmol L-1 [10]. Moreover, the finding that salvinorin A has 
similar potency and efficacy as U50488 in inhibiting cholinergic transmission is in 
accordance with other experiments in isolated cells (i.e. oocytes from Xenopus laevis, 
Chinese hamster ovary, HEK293) expressing !-opioid receptors [10–12]. It is 
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interesting to note that both salvinorin A and U50488 did not produce a total inhibition 
of the contractions evoked by EFS (Emax values in the 50–70% range), which is in line 
with the ability of U50488 to produce a partial inhibition (maximal inhibition: 55%) of 
electrically evoked acetylcholine release from guinea-pig myenteric neurones [26]. In 
preparing this manuscript, it has been noted that salvinorin A produced !-opioid 
agonist-like discriminative effects in rhesus monkeys [27] and decreased dopamine 
levels in the mouse caudate putamen through activation of !-opioid receptors [28]. In 
conclusion, it is reported here that the hallucinogenic herb Salvia divinorum exerted 
inhibitory effects on enteric cholinergic transmission in the guinea-pig ileum through 
activation of prejunctional !-opioid receptors. Salvinorin A may be the chemical 
constituent responsible for this activity. These data may justify the traditional use of 
the herb in the treatment of diarrhoea. 
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CHAPTER 2 
 
Effects in vivo of a new diterpenoid from Salvia cinnabarina with anxiolytic 
and antinociceptive properties. 
 
 
In a screening programme on 
Salvia medicinal plants (Fam. 
Lamiacae), a crude ethanolic extract 
from the aerial part of the plant Salvia 
cinnabarina M. Martens et Galeotti 
(figure 2.1) showed in vitro 
antispasmodic activity [1]. This led to 
the isolation of a new diterpenoid of 
the pimarane skeleton, the compound 
3,4-secoisopimar-4(18),7,15-triene-3-
oic acid (CMP1) [1] (Figure 2.2), 
whose complete relative 
stereochemistry was recently 
determined by an X-ray diffraction 
analysis of a single crystal of a suitable 
crystalline derivate [2]. Further studies 
have shown that CMP1 reduces 
intestinal motility in vivo [3], urinary 
bladder contractility in vitro both with 
a mechanism involving calcium 
channel [4] and possesses a weak 
hypotensive activity [5]. Diterpenoids 
are chemical compounds found in 
different plant species of the Salvia 
genus that possess a variety of 
biological activities including effects 
on the central nervous system (CNS) 
[6]. Salvinorin A (Salvia divinorum), 
miltirone, tanshinones IIA and IIB, 
carnosol and carnosic acid (Salvia 
officinalis) are examples of isolated 
diterpenes with hallucinogenic, 
neuroprotective, sedative and hypnotic 
properties [7-14].  
 
 
 
Figure 2.1: Salvia cinnabarina 
 
The possibility that CMP1 like 
other isolated diterpenoids might affect 
CNS was the main aim of these 
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investigations. For this reason 
anxiolytic and antidepressive activity 
of CMP1 were studied in the elevated 
plus-maze test and in the forced 
swimming test. Furthermore, CMP1 
was administered after a pre-treatment 
with pentobarbital and its effects on 
sedative activity were monitored. 
The CMP1 was also tested for its 
effects on spontaneous motor activity 
(total motility and locomotion) and 
several models of nociception have 
been used to examine the potential 
analgesic effects. These studies 
demonstrate for the first time that 
CMP1 has pronounced CNS depressant 
properties, manifested as 
antinociception, sedation and axiolitic 
effects.
 
 
 
Figure 2.2: CMP1 (3,4-secoisopimar-   
4(18),7,15-triene-3-oic acid) 
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2.1 MATERIAL AND METHODS 
 
2.1.1 Animal 
Male CD-1 mice (Charles River, Italy) weighing 25–30g were used for all 
experiments. The mice were housed in colony cages (7 mice in each cage) for at least 
1 week prior to experimental sessions under the following conditions: exposed to 
normal light (from 7.00 a.m. to 7.00 p.m.); temperature 22±1°C; relative humidity 
60±10%; and food and water available ad libitum. Animal care and their use 
conformed to the Italian Law Decree of 27/01/92, No.116. 
2.1.2 Elevated plus-maze test 
This test has been widely validated to measure anxiety in rodents [15,16]. The 
apparatus, constructed from black Plexiglas, consisted of two open arms (50cm*10cm 
each), two enclosed arms (50cm*10cm*40cm each) and a central platform 
(10cm*10cm), arranged in such a way that the two arms of each type were opposite to 
each other. The maze was elevated 60cm above the floor. Ten minutes after the i.p. 
treatment with CMP1 (1, 10, 50, 100mg kg-1) or thirty minutes after the i.p. treatment 
with diazepam (1 and 2mg kg-1) or vehicles, each animal was placed at the centre of 
the maze, facing one of the enclosed arms. During the 10 min test period, the number 
of open arm entries and the time spent therein was recorded [17]. The entry of each 
animal into an arm with all four paws was considered as end-point. Animal behaviour 
was observed by using a video camera located above the maze.  
2.1.3 Forced swimming test 
The test was performed as suggested by Lucki [18] and Porsolt [19] with little 
modification. The apparatus consisted of a transparent Plexiglas cylinder (50cm*20cm 
diameter) filled up to 30cm with water at room temperature. CMP1 (1 and 10 mg kg-1) 
or vehicle were administrated 10 min prior to the test. During the 10 min test, a trained 
observer recorded immobility or floating considered as when the mice made no further 
attempts to escape except the movements necessary to keep its head above the water. 
Reduction in immobility was considered an antidepressant-like action [20]. 
2.1.4 Pentobarbital-sleeping time 
Ten minutes after the i.p. treatment with CMP1 (1 and 10 mg kg-1) or thirty 
minutes after the i.p. treatment with diazepam (1 and 2 mg kg-1) or vehicles each 
animal was i.p. injected with  pentobarbital (50 mg kg-1) and the time passed for the 
mouse to be placed on its back was recorded as the sleep latency. Sleeping time was 
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taken as the period between the loss of the righting reflex and its return. The 
experiments were carried out in a quiet room where temperature was maintained at 
22±24°C during sleeping time.  
2.1.5 Spontaneous motor activity 
Locomotor activity was recorded with an infrared photocell activity monitor 
(Ugo Basile, Italy), provided with one array of 15 infrared photocells spaced  2.5 cm 
apart. Spontaneous motor activity was monitored during 30 min and, contextually, the 
number of times each animal reared and the time spent in horizontal walking were 
recorded. Measurements were performed between 10 a.m. and 1 p.m. .The animals 
were treated with CMP1 (1, 10 ,50, 100 mg kg-1) i.p. immediately before the start of 
the test. 
2.1.6 Motor coordination 
Motor coordination was evaluated as previously reported [21] by using a 
rotarod apparatus (Ugo Basile, Italy) consisting of a bar with a diameter of 3.0 cm, 
subdivided into five compartments by a disk of 24 cm in diameter. The bar rotated at a 
constant speed of 16 rev min-1. A preliminary selection of mice was made on the day 
of experiments excluding those that did not remain on the rotarod bar for two 
consecutive periods of 45secs each. The integrity of motor coordination was assessed 
on the basis of the number of falls from the rod in 45secs. The performance time was 
measured before and six more time at 10, 20, 30, 40, 50 and 60 mins after i.p. 
treatment with CMP1 (10 and 100 mg kg-1) or vehicle. 
2.1.7 Hot plate test 
The apparatus consisted of a metal plate 25x25 cm (Ugo Basile, Italy) heated to 
a constant temperature of 48±0.1°C. This low temperature stimulation was used to 
unravel possible hyperalgesic effects. A plastic cylinder 20 cm diameter, 18 cm high 
was placed on the plate. The time of latency (s) was recorded from the moment the 
animal was inserted inside the cylinder up to when it first licked its paws or jerked 
them off the hot plate. The measurement was terminated if the following occurred: 
The latency exceeded the cut-off time of 60 secs or if the mouse jumped off the hot 
plate. Baseline latency was 16–25 secs. For the baseline determination, the hot plate 
latency was recorded 90, 60 and 30 mins before treatment and at 15, 30, 45, 60, 90 and 
120 mins after  treatment [22]. In these experiments, CMP1 (10, 50, 100 and 500 mg 
kg-1, i.p.) or vehicle were injected immediately before the test.  
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2.1.8 Tail flick test 
Tail flick latency was obtained using a tail flick unit (Ugo Basile, Italy), 
consisting of an infrared radiant light source (100 W, 15 V bulb). A low lamp potential 
was utilised in order to unravel possible hyperalgesic effects. The light source was 
focused onto a photocell utilising an aluminium parabolic mirror. The mice were 
gently hand-restrained with a glove during the trials. Radiant heat was focused 1–2 cm 
from the tip of the tail, and the latency time (s) the mouse took to flick its tail was 
recorded. The measurement was terminated if the latency exceeded the cut off time 
(15 s). Baseline latency was 5–10 secs. Tail flick data were recorded as latency (s) 
both at 90, 60 and 30 mins before the treatment for baseline determination and at 15, 
30, 45, 60, 90 and 120 mins after the treatment [22]. In these experiments, CMP1 (10, 
50, 100 and 500 mg kg-1, i.p.) or vehicle were injected immediately before the test. 
2.1.9 Formalin test 
In the formalin test, 20 µl of a 1% solution of formalin in saline was injected 
subcutaneously into the dorsal surface of the right hind paw of the mouse, using a 
microsyringe with a 27-gauge needle. The formalin injection produced a distinct 
biphasic response consisting of licking or biting of the paw. The early phase occurred 
from 0 to 10 mins after the formalin injection and the late phase from 15 to 40 min. 
The mouse was placed in a Plexiglas cage (30*14*12 cm), utilised as an observation 
chamber, 1 h before administering the formalin injections. The total amount of time (s) 
that the animal spent licking or biting the paw after the formalin injection, at intervals 
of 5 mins was recorded for a period of 40 min [22]. Ten minutes after the i.p. 
treatment with CMP1 (1, 10 and 50 mg kg-1) or thirty minutes after the i.p. treatment 
with diazepam (2 mg kg-1) or vehicles, each animal was treated with formalin and the 
licking activity recorded for forty minutes. 
2.1.10 Toxicity 
Three groups of CD-1 female were treated p.o. with CMP1 at doses of 300, 
500 and 2000 mg kg-1 following the guidelines [23] OECD GUIDELINE FOR 
TESTING OF CHEMICALS Acute Oral Toxicity – Acute Toxic Class OECD/OCDE 
423 adopted 17th December 2001. 
2.1.11 Drugs and treatment procedure 
Extraction of CMP1 from leaf surface constituents of fresh aerial parts of 
Salvia cinnabarina was performed as previously described [1] (HPLC purity grade 
96%). The sodium salt (prepared by reaction with an equivalent quantity of NaOH in 
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MeOH solution and evaporation to dryness) was dissolved (5 mg) in distilled water. 
On each test day, an aliquot of drug solution were freshly dissolved in PBS and then 
i.p. injected in a volume of 35 mg kg-1. Diazepam solutions were prepared in distilled 
water added with Tween 80 (2 drops every 10 ml) and dispersed by ultrasound. 
Injections were given i.p. at a volume of 10 ml kg-1. 
2.1.12 Data analysis and statistics 
Experimental data were analysed using analysis of variance (ANOVA) 
followed by Bonferroni’s test procedure for verifying the significance between two 
selected means. For all the experiments, statistical significance was always assumed to 
be p<0.05. 
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2.2 RESULTS  
2.2a Elevated plus-maze test  
The results of these experiments are reported in figure 2.3. CMP1 was 
administered at doses of 1, 10, 50 and 100 kg-1 i.p. 10 mins before the test. Diazepam 
was administered at doses of 1 and 2 mg kg-1 i.p. 30 mins before the test. Data are 
reported as a percentage of the vehicle-induced effects. No behavioural differences 
were observed after the administration of CMP1 or diazepam vehicle. CMP1 
administered at a dose of 1 mg kg-1 did not change the time spent in the open arms or 
the number of entries into  the open arms compared to confront to vehicle-treated 
animals (figure 2.3). When administered at the dose of 10 mg kg-1, CMP1 was able to 
increase both the time spent in the open arms and the number of entries into the open 
arms (figure 2.3). Diazepam administered at a dose of 1 mg kg-1 was able to increase 
the number of entries into the open arms only, while at a dose of 2 mg kg-1 ,diazepam 
increased both the time and the number of entries into the open arms (figure 2.3).  
2.2b Forced swimming test 
CMP1 administered at doses of 1 and 10 mg kg-1 i.p. did not change the time of 
floating compared to vehicle-treated animals (data not shown).  
2.2c Pentobarbital-sleeping time 
In these experiments the treatment with CMP1 (1 and 10 mg kg-1) or with 
diazepam (1 and 2 mg kg-1) significantly increased the sleeping time induced by 
pentobarbital (figure 2.4). The increase in sleeping time observed after CMP1 or 
diazepam administrations were in the same order of magnitude, since no differences 
were found between CMP1 and diazepam treatments. The effects observed after 
CMP1 or diazepam administrations were independent of the dosage used and for the 
sake of simplicity, only the results obtained after highest dose administration were 
reported.  
2.2d Spontaneous motor activity 
The horizontal motor activity and the vertical motor activity were recorded 
after CMP1 (1, 10, 50 and 100 mg kg-1) administration. CMP1 administered at the 
lowest doses (1 and 10 mg kg-1) did not change the locomotor activity count of mice, 
in contrast to diazepam (2 mg kg-1) which reduced spontaneous motor activity (figure 
2.5). When administered at a dose of 100 mg kg-1 i.p, CMP1 strongly reduced the 
locomotor activity count of mice. 
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Figure 2.3. CMP1 effects in the plus maze test. TOA, time spent in the open arms; NEOA, number of 
entries in the open arms. Animals were treated i.p. 10 min before the test with CMP1 (1, 10, 50 and 100 mg kg-1) or 
30 min before the test with diazepam (D, 1 and 2 mg kg-1). [TOA] Vehicle (D) value was 27.92 ± 2.78% and 
Vehicle (CMP) value is 23.5± 4.52%; [NEOA] Vehicle (D) value was 36.76 ± 2.48% and Vehicle (CMP) value is 
27.5± 2.28%. * p<0.05, ** p<0.01 vs vehicle. (N= 12-15).  
 
 
 
                                     
Figure 2.4. CMP1 effects on the sleep induced by pentobarbital (50 mg kg-1, i.p.). Animals were treated 
i.p. 10 mins before the test with CMP1 (10 mg kg-1) or 30 mins before the test with diazepam (D, 2 mg kg-1). Data 
are reported as a percentage of the vehicle-induced effects (CMP1vehicle-treated animals: 1011±158 secs; D 
vehicle-treated animals: 1755±277 sec). * is for p<0.05 and ** is for p<0.01 vs  vehicle-treated animals. N, 15-20. 
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Figure 2.5 CMP1 effect on total spontaneous motor activity. Animals were treated i.p. 10 min before the 
test with CMP1 (1, 10, 50 and 10 mg kg-1) or 30 min before the test with diazepam (D, 2 mg kg-1). Results are 
expressed as mean ± s.e.m. * p<0.05, ** p<0.01 vs vehicle. (N= 12-15).  
 
 
               
 
2.2e Motor coordination 
Despite  the doses used (1, 10 and 100 mg kg-1, i.p.) CMP1 did not change the 
motor coordination of mice (data not shown). 
2.2f Hot plate test 
The nociceptive latency evoked by thermal stimuli applied by the hot plate are 
reported in figure 2.6. In animals treated with CMP1 at  dose of 10, 50, 100 and 500 
mg kg-1 there was no significant difference compared to vehicle-treated animals. 
However, a slight reduction in time latency was observed after CMP1 administration 
at doses of 10 and 50 mg kg-1 (figure 2.6). Furthermore, a slight increase in time 
latency was recorded after CMP1 administration at  dose of 500 mg kg-1 (figure 2.6).  
2.2g Tail flick test 
The results obtained in the tail flick test are reported in figure 2.6. In animals 
treated with CMP1 at  dose of 10, 50, and 100 mg kg-1 there was no significant 
difference compared to vehicle-treated animals. When CMP1 was administered at a 
dose of 500 mg kg-1 a strong increase in the latency of the mice to respond was 
observed (figure 2.7).  
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Figure 2.6. CMP1 effects in the hot plate 
test. Animals were treated with CMP1 (10, 50, 100 
and 500 mg kg-1) i.p. immediately before the test 
starts. V is for vehicle-treated animals. N, 8. 
 
 
Figure 2.7. CMP1 effects in the tail flick 
test. Animals were treated with CMP1 (10, 50, 100 
and 500 mg kg-1) i.p. immediately before the test 
starts. V is for vehicle-treated animals. ** is for 
p<0.01 vs vehicle-treated animals. N, 8. 
 
2.2h Formalin test 
In these experiments, CMP1 administered at doses of 10 and 50 mg kg-1 i.p. 
was able to reduce the early phase of the formalin test (figure 2.8, panel A). On the 
contrary, CMP1 did not change the licking activity recorded in the late phase of the 
formalin test. In these experiments, the effects of diazepam were also investigated. 
Diazepam administered at the dose of 2 mg kg-1 was able to reduce the late phase of 
the formalin test showing a slight but not significant difference in the early phase 
compared to vehicle-treated animals (figure 2.8, panel B).  
2.2i Toxicity 
The CMP1 toxicity evaluated following the guidelines OECD/OCDE 423 
adopted 17th December 2001 gave a LD50 >500 mg kg-1. 
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Figure 2.8. CMP1 effects in the formalin test. In the panel A, the licking activity recorded from 0 to 40 
mins after formalin injection is reported. In the panel B both the early and the late phase are reported. CMP1 (10 
and 50 mg kg-1, i.p.) was administered 10 mins before formalin. Diazepam (D, 2 mg kg-1, i.p.) was administered 30 
mins before formalin. V-CMP1, CMP1 vehicle-treated animals. V-D, diazepam vehicle-treated animals. * is for 
p<0.05 and ** is for p<0.01 vs vehicle-treated animals. N, 8-9. 
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2.3 DISCUSSION 
 
It is known that plants have played an important part in the development of 
new drugs and it is estimated that at least 25% of the molecules currently used as 
prescribed drugs originate, directly or indirectly, from plant sources [24]. There are 
numerous traditional medicinal plants with a reputation for affecting CNS functions 
and activities. Among these plants, Salvia species are prominent for their reputed 
beneficial effect on CNS disorders. Their crude or semipurified extracts show an 
efficacy that is the result of the combined action of several types of compounds so that 
the final effect is often of weak or mild intensity. Efforts directed to obtain the active 
principle(s) from plants of genus Salvia have led to identifying a class of compounds 
of diterpenoid structures. In this context, this work has aimed to investigate  the 
potential central effects of the CMP1, the major diterpenoid constituent of Salvia 
cinnabarina. These results demonstrate for the first time that CMP1 has pronounced 
CNS depressant properties, manifested as sedation, axiolitic effects and 
antinociception.  
In these experiments, CMP1 showed anxiolitic effect evaluated either as the 
time spent inside and as the number of entries into the open arms in the plus maze 
paradigms. Similar effects were observed after diazepam administration at a dose of 2 
mg kg-1, since the lowest dose of diazepam (1 mg kg-1) did not modify the number of 
entries into the open arms. Furthermore, these findings demonstrated sedative 
properties for CMP1 since it increases the time of sleep after pentobarbital injections 
already at the lowest dose (1 mg kg-1). In these last experiments CMP1 increases 
pentobarbital-induced sleep as diazepam did. However, it is well-known that 
diazepam-induced sedative effects are paralleled by a reduction in  spontaneous motor 
activity [25]. These experiments furthermore, have shown that CMP1 did not change 
the spontaneous motor activity at sedative doses. These findings are of interest, since 
sedative effects should arise without affecting locomotor activity.  
These anxiolitic and sedative properties were also observed using polar extracts 
from other species of Salvia. The hydroalcoholic extract of Salvia reuterana Boiss 
increased the percentage of time-spent and the percentage of arm entries in the open 
arms of the elevated plus-maze [26]. In the same way, the hydroalcoholic extract of 
Salvia elegans increased the percentage of time spent and the percentage of arm 
entries into the open arms of the elevated plus-maze, and also increased increase the 
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time the mice spent  in the illuminated side of the light-dark test [27]. However, the 
hydroalcoholic extract of Salvia elegans also increased  the immobility time of mice 
subjected to the forced swimming test [27]. These finding were confirmed by Mora 
[28] who found a hydroalcoholic extract from the leaves of Salvia elegans able to 
increase at a dose of 12.5 mg kg-1 the exploration of the open arms of the pus maze 
and with all dose used (3.12, 12.5, 25 and 50 mg kg-1) a reduction of immobility in the 
forced swimming test. These anxiolitic and anti-depressive effects were similar to 
those observed after diazepam (1 mg kg-1) and fluoxetin (10 mg kg-1) respectively 
[28]. 
The antinociceptive activities of diterpenoid from Salvia species are already 
reported. Salvinorin A, the active constituent of Salvia divinorum induces profound 
hallucinations and binding studies suggest that the biological activity of salvinorin A 
involves the kappa-opioid receptor. Functional studies confirm the involvement of 
kappa-opioid receptor in the mechanism of salvinorina A effects. Salvinorin A 
increased tail-flick latencies and the pretreatment with the kappa-opioid receptor 
antagonist nor-binaltorphimine attenuated the salvinorin A induced increase in tail-
flick latency whereas the mu-opioid receptor antagonist beta-funaltrexamine and the 
delta-opioid receptor antagonist naltrindole were ineffective [29]. These observations 
were further demonstrated by Ansonoff [30], who found the intracerebroventricular 
injection of salvinorin A able to produce antinociception in wild-type mice but not in a 
novel strain of kappa-opioid receptor knockout mice. Furthermore, salvinorin A 
reduces rectal body temperature in a similar way to conventional kappa-opioid 
receptor agonists, in a genotype-dependent manner. In the experiments, we cannot 
exclude an involvment of opioid receptor in the mechanism of CMP1-induced 
antinociceptive effects, since CMP1 was able to change the response to thermal 
stimuli in the tail flick test and CMP1 reduced the early phase of the formalin test. 
However, the increase of latencies obtained in the tail flick test was observed only at 
the highest dose tested and no effects were observed in the hot plate test after CMP1 
administration. It is well known that opioids are also able to increase  the response to 
thermal stimuli in the hot plate test and opioids are able to reduce both the early and 
the late phase of the formalin test [31]. From all the above findings, further 
mechanisms other than opioid receptors involvement might explain antinociceptive 
effects induced by CMP1 in mice.  
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CMP1 was isolated from Salvia cinnabarina, but other Salvia species are 
reported to induce antinociception in animals. Water extracts of Salvia africana-lutea 
L. significantly reduced the writhes induced by acetic acid administration and 
significantly delayed the reaction time  of mice to thermal stimulation produced by the 
hot plate [32]. The crude acetone and methanol extracts of Salvia aegyptiaca L. caused 
dose-related inhibition of acetic acid-induced abdominal constriction and significantly 
reduced formalin-induced pain. It also significantly increased the reaction time in the 
hot-plate test [33]. The above findings and our data further suggest Salvia species as a 
useful tool for the identification and the development of new analgesic drugs. 
These findings further suggest that in the extracts from various Salvia species 
CMP1 isolated to date only from Salvia cinnabarina, is one of the active compounds 
with anxiolitic and antinociceptive activity. The interesting activities of CMP1 lead 
towards the identification of more effective derivatives. Our findings also indicate that 
CMP1 may be appropriate for the treatment of psychiatric ailments or pain treatment, 
also considering that the pharmacological activity is exerted without affecting 
spontaneous motor activity. 
Further in vitro and in vivo studies are necessary to determine structure-activity 
relationships and the exact mechanism/s of action.  
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CHAPTER 3 
 
Effect of a Diterpenoid from Salvia cinnabarina on Arterial Blood Pressure 
in Rats. 
 
 
The genus Salvia is known for 
its wide spectrum of pharmacological 
properties, such as antioxidant, 
antifungal, antinociceptive, anti-
bacterial, antiinflammatory [1-3].  
Salvia cinnabarina is an 
American species in the subgenus 
Calosphace, section Incarnate [4]  
containing a high amount of 
oxygenated monoterpenes (particularly 
linalool) and oxygenated 
sesquiterpenes [5]. The new secoiso- 
pimarane diterpenoid, namely3,4-
seicosopimar-4(18),7,15-triene-3-oic 
acid (CMP1), recently isolated from the 
leaf exudates of aerial parts of S. 
cinnabarina , has been shown to have 
intestinal spasmolytic activity in vitro, 
with an aspecific mechanism [6]. In 
vivo, CMP1 inhibits mouse intestinal 
motility with a mechanism involving 
L-type Ca2+ channels [7]. 
Furthermore, CMP1 inhibits rat bladder 
contractility in vitro with the partial 
involvement of nitric oxide [8]. To 
further characterize the pharma-
cological profile of CMP1, in the 
present study we have investigated the 
effect of CMP1 on rat arterial blood 
pressure. 
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3.1 MATERIAL AND METHODS 
 
3.1.1   Animal 
Male Wistar rats (200–250 g; Harlan Nossan), housed under conditions of 
constant temperature (22– 24 °C) and humidity (50 ± 10%) under a 24 h light– dark 
cycle with food and water freely available, were used for the experiments. All animal 
experiments complied with the Italian D.L. no. 116 of 27 January 1992 and Associated 
Guidelines in the European Communities Council Directive of 24 November 1986 
(86/609/ ECC). 
3.1.2   Drugs. 
 Urethane, N+-nitro L-arginine methyl ester (L- NAME) and heparin were 
purchased from Sigma (Milan, Italy). Chlorisondamine was purchased from Tocris 
(UK). Extraction, isolation and structural characterization of CMP1 were performed as 
described previously (Romussi et al., 2001). HPLC analysis indicated that CMP1 was 
96% pure. 
3.1.3   Measurement of arterial blood pressure.  
 Male Wistar rats were anaesthetized with urethane (sol 10% w/v i.p.) and 
placed supine on an operating table. The right jugular vein was cannulated for drug 
administration, the left carotid artery was cannulated with a cannula containing 
heparinized saline (5 U/mL) and connected to a pressure transducer (Basile, Comerio 
(VA), Italy) for continuous monitoring of arterial blood pressure. Acquisition data 
were performed by a computerized system PowerLab (ADInstruments, v 3.4.3). After 
surgery, the arterial blood pressure was allowed to stabilize for about 30 min. The 
effect of three different doses (3, 10 and 30 mg/kg i.v.) of CMP1 was tested in 
different groups of animals. Each dose was administered on three consecutive times, 
for 20 min each, in the same animals. Subsequently, a single administration of CMP1 
(3 mg/kg i.v.) was chosen, after the preliminary experiments in which each dose was 
administered for three consecutive times in the same animal. 
3.1.4   Ganglion-blockade experiments. 
 To eliminate any influence of autonomic nervous system activation on 
changes in mean arterial blood pressure (MABP) induced by CMP1, different groups 
of animals were pretreated with the irreversible ganglion-blocking agent 
chlorisondamine at a dose of 2.5 mg/kg i.p., before administering CMP1 (3 mg/kg i.v.) 
and changes in blood pressure were evaluated. 
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3.1.5   Role of nitric oxide. 
 The role of nitric oxide was assessed by infusing L-NAME (0.3mg/kg/min 
i.v.), through a butterfly needle inserted into the caudal vein, in ganglion blocked rats 
and changes in blood pressure induced by CMP1 (3 mg/kg i.v.) were evaluated and 
compared with values obtained before the infusion. The dose of L-NAME chosen was 
able to restore blood pressure in ganglion-blocked rats to the normal value. 
3.1.6   Statistical analysis. 
 Changes in MABP have been evaluated as the difference from the basal value 
or as the percentage change from the baseline, when groups with different basal blood 
pressure were compared. The results obtained are expressed mean ± SEM and 
analysed by one-way analysis of variance (ANOVA) followed by Bonferroni’s or 
Dunnett’s test, as appropriate. When requested, Student’s t-test was used. A value  of  
p < 0.05 was considered statistically significant. 
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            3.2 RESULTS AND DISCUSSION 
 
Intravenous administration of CMP1 (3–10 mg/kg i.v.) into anaesthetized rats 
caused a transient dose-dependent fall in MABP. The dose of 3 mg/kg i.v. caused a 
fall of 14.75 ± 1.44 mmHg; there was no tachyphylaxis after repeated administrations 
of 20 min each into the same animal and so this dose was chosen for all successive 
experiments (Fig. 3.1).                                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Decrease in MABP induced by CMP1 (3, 10 and 30 mg/ kg i.v.) in anaesthetized rats. Each 
dose of CMP1 was administered in different groups of rats and repeated into the same animals three consecutive 
times at 20 min intervals (n = 5).  
 
 
 
Hypotension induced by CMP1 (3 mg/kg i.v.) was associated with a fall in 
heart rate from 443 ± 24 to 264 ± 44 beats per minute (bpm) (p < 0.01; n = 9). To 
differentiate between a central and a peripheral effect of CMP1, experiments were 
performed in groups of rats treated with the irreversible ganglion-blocking agent 
chlorisondamine (2.5 mg/kg i.p.). After treatment with chlorisondamine, the MABP 
value was 54.64 ± 1.59 mmHg (n = 11), significantly different from the control value 
(p < 0.0001); however, the hypotensive effect of CMP1, evaluated as the percentage 
(%) change in MABP, was not different from the control animals (21.50 ± 6.76% vs 
16.00 ± 2.38%), suggesting that it does not involve the autonomic nervous system 
activation deriving from a central effect of CMP1. Interestingly, in ganglion-blocked 
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rats the hypotensive effect of CMP1 was followed by a slight but significant 
hypertension (10.75 ± 2.14%; n = 4) that was not evident before ganglion-blockade. 
Several studies describing the effect of L-NAME on changes in MABP induced by 
drugs have been performed in normal animals, in which the substantial increase in 
MABP and vascular resistance above physiological values, due to nitric oxide 
inhibition, might activate a reflex response masking the real effect of drugs. For this 
reason, to investigate on the possible role of nitric oxide on changes in blood pressure 
induced by CMP1, experiments were performed on ganglion-blocked rats, in which an 
infusion of L-NAME (0.3 mg/kg/min i.v.) restored blood pressure to the normal value. 
Under these conditions, no inhibition of CMP1-induced hypotension was observed, 
ruling out the involvement of nitric oxide (Fig. 3.2A).  
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Figure 3.2. Change in MABP induced by CMP1 in ganglion-blocked rats and effect of L-NAME infusion. 
(a) Decrease in MABP induced by CMP1 (3 mg/kg i.v.) before (white bar), after treatment with the ganglion-
blocking agent chlorisondamine (2.5 mg/kg i.p. solid bar) and in ganglion-blocked rats treated with an infusion of 
L-NAME (0.3 mg/kg/min i.v. hatched bar). (b) Increase in MABP induced by CMP1 (3 mg/kg i.v.) before (white 
bar), after treatment with ganglion-blocking agent chlorisondamine (2.5 mg/kg i.p. solid bar) and in ganglion-
blocked rats treated with an infusion of L-NAME (0.3 mg/kg/min i.v. hatched bar) (n = 4–8, * p < 0.01 vs before 
treatment with chlorisondamine and vs after L-NAME infusion).  
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This finding, together with the observation that in ganglion-blocked rats 
CMP1-induced hypotension was not different from the value obtained in normal, non-
ganglion-blocked rats, suggests that the vasodilator mechanism is due to a peripheral 
action but independent from nitric oxide release. Interestingly, following L-NAME 
infusion, hypertension that was evident only after chlorisondamine treatment was 
abolished (Fig. 3.2B). 
 In conclusion, this is the first work demonstrating an in vivo hypotensive 
effect of CMP1 due to a direct peripheral action but independent of nitric oxide 
release. Our findings further contribute to delineate the pharmacological profile of this 
natural compound. 
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CHAPTER 4 
 
Platelet antiaggregating activity and chemical constituents of Salvia jamensis 
J. Compton 
 
A phytochemical study has 
been carried out on the surface exudate 
of Salvia x jamensis (figure 4.1) which 
showed a significant platelet 
antiaggregating activity. Platelet 
aggregation inhibitors are widely used 
in thromboembolic diseases. Since  
currently available compounds have 
various limitations, it is desirable to 
find new types of platelet 
antiaggregating agents, which prevent 
the initiation of thrombus formation.  
 
 
 
Figure 4.1: Salvia jamensis 
 
The surface exudate of Salvia x 
jamensis J. Compton, obtained by 
rinsing the plant material with 
methylene chloride and terpenic 
compounds isolated have been tested 
on ADP-induced platelet aggregation. 
The known compounds isopimaric acid 
(compound 2), 14-!-hydroxy-
isopimaric acid (compound 3), 3-"-
hydroxy-isopimaric acid (compound 4), 
3"-dihydrosalviacoccin (compound 5), 
betulinic acid (compound 6), ursolic 
acid (compound 7) (figure 4.2) were 
isolated together with the new 
diterpene (compound 1) (figure 4.3).  
The structure of compound 1 
was determined as 15, 16-epoxy-
cleroda-3-en-7!, 10"-dihydroxy-12,17, 
19,18-diolide on the basis of 
spectroscopic data analysis.  
Among all tested compounds, 2 
showed a significant concentration-
dependent antiaggregating activity 
when ADP (3 "M) was used as agonist 
on rat platelets. Conversely, 1 
increased ADP–induced platelet 
aggregation.
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Figure 4.2: known diterpenoids and triterpenoids isolated from Salvia jamensis 
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Figure 4.3: new diterpene isolated from Salvia jamensis (compound 1)  
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4.3 MATERIAL AND METHODS 
 
4.1.1   Plant Material 
Aerial parts of S. x jamensis J. Compton were obtained from the collections of 
Salvia species established and available in the Istituto Sperimentale per la Floricoltura 
(Sanremo, Italy) and Centro Regionale di Sperimentazione ed Assistenza Agricola 
(Albenga. Italy). Dr. Gemma Bramley has identified the species and a voucher 
specimen is deposited in Kew Herbarium (K). 
4.1.2   Extraction and isolation 
For the isolation of leaf surface constituents, fresh aerial parts (3.1 kg) were 
immersed in CH2Cl2 for 20 sec. After filtration the extraction solvent was removed 
under reduced pressure. The exudate (18 g) was chromatographed in portions of 1.5 g 
on Sephadex LH-20 columns (60 x 3 cm) using CHCl3/MeOH (7:3) as eluent to give 
in order of elution fractions (3g) with waxy compounds (170 mL), fractions (3g) with 
very crude compound 7 (from 170 mL to 220 mL) and fractions (12g) with mixture of 
compounds 1-7 (from 220 mL to 290). These last fraction groups were 
chromatographed in portions of 4 g on silica gel columns (40 x 4 cm) eluting with 
mixtures of n-hexane- CHCl3 [50:50 (4.1 L), 40:50 (2.1 L), 33:67 (1.0 L), 25:75 (1.0 
L), 10:90 (11.0 L], then with CHCl3 (8.3 L), and then with CHCl3-MeOH [95:5 (3.4 
L)]. Elution with n-hexane-CHCl3 40:50 (from 0.2 L to 2.1 L) and with with n-hexane-
CHCl3 33:67 and 25:75 afforded fractions with compound 2 (crystallized from MeOH: 
2.05 g). Elution with with n-hexane-CHCl3 10:90 afforded first fractions with 
compound 6 (from 1.0 to 1.4 L; crystallized from EtOH: 0.2 g), then fractions with 
compound 7 (from 1.6 to 2.7 L; crystallized from EtOH: 1.4 g), then fractions with 
compound 5 (from 2.7 to 3.0 L; crystallized from CHCl3/MeOH: 0.14 g), then with 
compound 1 (from 3.8 to 11.0 L; crystallized from CHCl3/MeOH: 0.58 g). Elution 
with CHCl3 afforded fractions with 3 (from 3.5 to 6.0 L; crystallized from 
MeOH/H2O: 0.25 g ). Elution with CHCl3-MeOH 95:5 afforded fractions with 
compound 4 (from 1.1 to 2.0 L, crystallised from MeOH/H2O: 50 mg).  
4.1.3   Animal 
Male Wistar rats (Harlan - Nossan) weighing 200-250 g, housed under 
conditions of constant temperature (22 – 24 °C) and humidity (50 ± 10 %) under a 
24 h light–dark cycle  with food and water freely available, were used for all 
experiments. All animal experiments complied with the Italian D.L. no. 116 of 27 
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January 1992 and associates guidelines in the European Communities Council 
Directive of 24 November 1986 (86/609/ECC).  
4.1.4   Platelet preparation and aggregation 
Blood was withdrawn by cardiac puncture from male Wistar rats, slightly 
anaesthetised with enflurane, and anticoagulated with 3.8% (w/v) trisodium citrate 
(1:9 v/v). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared as 
previously described [1]. Platelet rich plasma (PRP) was prepared by centrifugation of 
the anticoagulated blood at 250 x g for 10 min. The Platelet count in PRP was adjusted 
to 3x105 platelets "l-1 with autologous PPP. To prepare washed platelets suspension 
(WPS), PRP was diluted with an equal volume of citric acid/ sodium citrate buffer and 
centrifuged at 650 x g for 10 minutes. The platelet pellet was suspended in calcium-
free Tyrode’s buffer, centrifuged to 650 x g for 10 mins and then resuspended in a 
volume of calcium-free Tyrode’s buffer to obtain the final platelet concentration of 
3x105 platelets "l-1. Platelet aggregation was monitored in an Elvi 840 light 
transmission aggregometer by measuring changes in turbidity of 0.25 ml PRP warmed 
at 37°C and under continuous stirring. ADP (3-10 "M) was used as aggregating agent. 
After preliminary experiments, the concentration of 3 "M ADP was chosen and used 
throughout  the study.  
To evaluate the effect of compounds 1-7 on ADP-induced platelet aggregation, 
5 "l of compounds tested, were added to PRP 5 minutes before the ADP (3 or 10 "M) 
at the final concentrations ranging between 2 x 10 -4 and 10 -3 M. As a control, an 
equal volume of DMSO (dimethyl-sulfoxide) was added to PRP. 
4.1.5   Data analysis and statistics 
Ex vivo data of platelet aggregation are presented as % aggregation relative to 
PPP or suspension buffer. For statistical analysis, a computerized statistical package 
was used (11). Data were analyzed by one-way ANOVA followed by Dunnett’s test 
vs. vehicle (n=10) for multiple comparisons. Vehicle (DMSO) value was 27.92 ± 2.78 
%. All results are expressed as means ± s.e.m. Values of p< 0.05 and p< 0.01 were 
considered significant. 
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4.3 RESULTS 
 
4.2.1    Effects of exudate from aerial part of Salvia x jamensis and of 
compounds 1-7 on ADP(3 !M) -induced platelet aggregation  
The surface exudate of Salvia x jamensis J. Compton, obtained by rinsing the 
plant material with methylene chloride, showed, at concentration of 100 – 500 "g/ml, 
a concentration – dependent trend toward a platelet antiaggregating activity (figure 
3.4). 
 
 
 
 
Figure 4.4: Effects of exudate from aerial 
part of Salvia x jamensis on ADP (3 "M) -induced 
platelet aggregation. Results are expressed as mean 
± s.e.m. and represent aggregation (%) in response 
to ADP 3"M alone (control) or in presence of 
DMSO (vehicle) or exudate of Salvia x jamensis 
(exudate 100-500 µg mL-1). (n=10) 
 
Compound 2 (HPLC analysis: one single peak) at concentrations of 6 x 10-4 
and – 1 x 10-3 M inhibited significantly ADP (3 "M) – induced platelet aggregation. 
Compounds 3 – 4 did not modify platelet aggregation in a significant manner. On the 
contrary, compound 1 (HPLC analysis: one single peak) increased at the highest 
concentration ADP- induced platelet aggregation (Table 3.A and figure 4.5). 
 
% platelet aggregation  
Compound (2 x 10 -4) M (6 x 10 -4) M (1 x 10 -3) M 
1 48.10 ± 14.06 29.83 ± 7.15 62.67 ± 8.88 ** 
2 18.36 ± 2.89 5.38 ± 3.11 ** 2.29 ± 1.35 ** 
3 33.58 ± 9.01 21.02 ± 4.66 16.71 ± 4.03 
4 46.66 ± 3.34 34.57 ± 5.14 22.38 ± 3.72 
 
Table 4.A: Results are expressed as mean ± s.e.m. and represent aggregation (%) in response to ADP 
3"M. In brackets are reported concentrations (M) of compounds tested. Vehicle (DMSO) value was 27.92 ± 2.78%. 
** p< 0.01 one way ANOVA followed by Dunnett’s test vs vehicle (n=10) 
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Figure 4.5: Effects of compounds 1-7 from aerial part of Salvia x jamensis on ADP (3 "M) -induced 
platelet aggregation. Results are expressed as mean ± s.e.m. and represent aggregation (%) in response to ADP 3 
"M alone (control) or in presence of DMSO (vehicle) or compounds 1-7 (2 x 10 -4; 6 x 10 -4; 1 x 10 -3 M). ** p< 
0.01 and one way ANOVA followed by Dunnett’s test vs. vehicle (n=10). 
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4.2.2   Effects of exudate from aerial part of Salvia x jamensis and compounds 
1-7 on ADP(10 !M) -induced platelet aggregation  
The exudate of Salvia x jamensis J. Compton did not show, at a concentration 
of 100 – 500 "g/ml, significant effects on ADP(10 "M) -induced platelet aggregation 
(figure 4.6). 
In compounds 1-7 only compound 2, at concentrations of 1 x 10-3M, showed 
inhibitory effect on ADP (10 "M) -induced platelet aggregation (5.931±) (figure 4.7).  
 
 
 
 
 
Figure 4.6: Effects of exudate from aerial 
part of Salvia x jamensis on ADP (10 "M) -induced 
platelet aggregation. Results are expressed as mean 
± s.e.m. and represent aggregation (%) in response 
to ADP 10 "M alone (control) or in presence of 
DMSO (vehicle) or exudate of Salvia x jamensis 
(exudate 100-500 µg mL-1). (n=10). 
 
 
 
Figure 4.7: Effects of compounds 1-7 from aerial part of Salvia x jamensis on ADP (10 "M) -induced 
platelet aggregation. Results are expressed as mean ± s.e.m. and represent aggregation (%) in response to ADP 10 
"M alone (control) or in presence of DMSO (vehicle) or compounds 1-7 (2 x 10 -4; 6 x 10 -4; 1 x 10 -3 M). * p< 0.05 
one way ANOVA followed by Dunnett’s test vs. vehicle (n=10). 
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4.3 DISCUSSION 
 
Platelet aggregation is a complex process. It is generally held that platelet 
activation is mainly mediated through the adhesiveness of platelets to the site of injury 
and through the action of endogenous agonists such as ADP, collagen, and thrombin, 
followed by the release of TXA2, which acts as an amplifying factor in the platelet 
aggregation [2-3](Jackson et al., 2003; Farndale et al., 2004). It is well established that 
platelets form aggregates in response to a number of stimuli, readily demonstrated in 
vitro using the aggregometer [4], and in vivo using radiolabelled platelets [5]. 
Intravenous administrations of ADP induce accumulation of platelet microaggregates 
which display spontaneous disaggregation [5]. In vitro ADP, at high concentrations, 
induces irreversible formation of platelet aggregates [6]. 
It is well known that some natural compounds show a wide variety of 
pharmacological effects on platelet aggregation [7-9] In previous papers the inhibition 
of platelet aggregation by diterpenes of abietane groups and by triterpenoids was also 
described , so what is examined here are the possible effects of exudate from aerial 
part of Salvia x jamensis and compounds 1-7 on ADP (3 or 10 "M) -induced platelet 
aggregation.  
The observed trend toward the platelet anti-aggregating effect of the surface 
exudate of Salvia x jamensis is likely due to the presence of the active compound 2; 
however, compound 3 (HPLC analysis indicated that the compound was 97% pure) 
shows an inhibitory trend, although not significant. It is worth noting that compound 3 
in comparison with 2 differs as to the presence in the molecules of a hydroxyl group. 
This suggests that reduced activity could be due to a reduced lipophylicity. Compound 
4 (HPLC analysis: one single peak), that is an isomer of 3, loses the observed 
biological activity. Compounds 5 – 7 were completely inactive (data not shown). The 
inactivity of compound 7 on ADP – induced platelet aggregation has already been 
described [10]. All these results suggest that pimarane, isopimarane and abietane 
derivatives may be useful for the semisynthesis of new compounds with platelet 
antiaggregating activity. 
 
 
 
 
79 
REFERENCES 
1. Cicala C, Santacroce C, Itoh H, Douglas GJ, 
Page CP. A study on rat platelet 
responsiveness following intravenous 
endotoxin administration. Life Sci. 1996 60, 
31- 38. 
2. Jackson SP, Nesbitt WS, and Kulkarni S. 
Signaling events underlying thrombus 
formation. J Thromb Haemost 2003 1:1602–
1612. 
3. Farndale RW, Sixma JJ, Barnes MJ, and De 
Groot PG The role of collagen in thrombosis 
and hemostasis. J Thromb Haemost 2004 
2:561–573. 
4. Born GV. The fate of 5-hydroxytryptamine 
in a smooth muscle and in connective tissue. 
.J Physiol. 1962 Apr;161:160-74. 
5. Page CP, Paul W, Morley J. An in vivo 
model for studying platelet aggregation and 
disaggregation.J Thromb Haemost. 1982 
Jun 28;47(3):210-3. 
6. G.V.R Born. Aggregation of blood platelets 
by adenosine diphosphate and its reversal. 
Nature. 1962 Jun 9;194:927-9. 
7. Cheung HTA, Fu S-L, Smal MA Inhibition 
of Platelet Aggregation by diterpenes Acids 
from Pinus massoniana Resin. Drug. Res. 
1994 44, 17-25. 
8. Lee AR, Wu WL, Chang WL, Lin HC, King 
ML. Isolation and bioactivity of new 
tanshinones. J Nat Prod. 1987 Mar-
Apr;50(2):157-60 
9. Jin JL, Lee YY, Heo JE, Lee S, Kim JM, 
Yun-Choi HS. Anti-platelet pentacyclic 
triterpenoids from leaves of Campsis 
grandiflora. Arch Pharm Res. 2004 
Apr;27(4):376-80. 
10. Saeed Sheikh SA, Farnaz S, Simjee 
Rukhsana U, Malik A.Triterpenes and "-
sitosterol from Piper betel: isolation, 
antiplatelet and anti-inflammatory effects. 
Biochemical Society Transactions 1993 21, 
462S. 
 
 
 
 
 
 
 
 
 
RINGRAZIAMENTI 
 
 
A conclusione del mio lavoro di tesi mi sembra doveroso ringraziare tutti 
coloro che in questi tre anni mi hanno sostenuto e guidato. Innanzitutto vorrei 
ringraziare il mio Tutor, il Prof. Nicola Mascolo per avermi dato la possibilità di 
vivere un’esperienza unica e stimolante e per la continua disponibilità con la quale mi 
ha seguito durante il corso di Dottorato. 
Grazie alla Prof.ssa Carla Cicala, alla Prof.ssa Santamaria, al Prof. Izzo al Prof. 
Capasso e a tutto il Dipartimento di Farmacologia Sperimentale della Facoltà di 
Farmacia di Napoli. 
Grazie alla Prof.ssa Maria Valeria D’Auria, attenta coordinatrice di questa Scuola di 
Dottorato. 
Un lavoro di tesi è fatto soprattutto della quotidianità del laboratorio e per 
questo sento di dover ringraziare tutti coloro che mi hanno accompagnato in questo 
cammino. Un ringraziamento particolare va al Dott. Stefano Pieretti responsabile del 
gruppo di ricerca con il quale ho lavorato in questi anni presso il Dipartimento del 
Farmaco, Reparto di Farmacologia per la Salute del Bambino e della Donna, Istituto 
Superiore Di Sanità, Roma. 
Ringrazio la Dott.ssa Amalia Di Giannuario e tutti i ragazzi che hanno lavorato 
con me. Ringrazio di cuore il mio Supervisore, la Dott.ssa Mariantonella Colucci per 
essersi dimostrata una “vera” professionista nonché una meravigliosa amica, grazie 
perché hai saputo regalarmi un sorriso nelle situazioni peggiori.  
Ringrazio di cuore tutti i miei amici di Roma, ringrazio la piccola Giò, Maria, 
Antonio, Guglielmo ed Enzo per il loro affetto sincero e per il continuo ed instancabile 
sostegno morale che mi forniscono da tempo, sono felicissima del legame speciale che 
mi unisce a voi. 
Un ringraziamento speciale va a mio padre e a mia madre, per il bene 
smisurato che continuamente mi dimostrano e per tutti i sacrifici fatti in questi anni, 
non credo che basti farvi sapere che siete la mia stella polare soprattutto in questo 
periodo. Ho sempre ammirato la vostra forza e il vostro “amore”, nella mia nuova vita 
mi ispirerò a voi… 
 
Alla mia “piccina” dedico questa tesi, in questi anni sono stata una sorella 
lontana, sempre poco “disponibile” ma non ho mai smesso di volerti bene e soprattutto 
di credere che sei unica, grazie di esserci. 
Ringrazio infine una persona speciale che ha cambiato la mia vita. Arturo 
grazie perché hai scelto di condividere con me la tua vita. 
 
